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Abstract 
 
The RhD blood group antigen is among the most clinically significant blood 
group antigens and as such, RhD negative individuals are transfused with 
RhD negative red cells to avoid the production of antibodies and potential 
delayed transfusion reaction. Whilst RhD negativity is most commonly caused 
by a complete deletion of the RHD gene, a wide array of RHD variants exist 
due to the highly polymorphic nature of the gene. These variants can express 
very low levels of the RhD antigen that is not detectable by the current 
serological testing. These are defined as the “DEL phenotype”, and are 
misclassified as RhD negative.  A range of variant RHD alleles can generate 
the DEL phenotype and at least one type; the RHD(K409K), can be 
immunogenic if transfused to an RhD negative patient and is therefore of most 
clinical significance. A pilot genotyping study utilised a crude exon scanning 
method that required outsourcing for the classification of the RHD variant and 
determined 2.17% of a subset of RhD negative donors carry DEL associated 
alleles. With no routine molecular testing in place at the Blood Service, the 
development of an efficient, high throughput method, tailored to detecting the 
unique Australian distribution of RHD variants is therefore paramount. 
 
The first aim was to develop a qPCR exon scanning strategy to determine the 
presence of hybrid RHD-CE alleles, intact RHD alleles or true RHD negative 
donations in RhD negative individuals. Three multiplex qPCR assays were 
developed to detect 8 of the 10 exons of the RHD gene. The test was 
validated using a panel of 49 blinded samples. This strategy defines the 
presence of hybrid or intact RHD alleles but cannot resolve the difference 
between an RhD negative or DEL associated allele. 
  
The second aim was to develop and validate a targeted MGB qPCR to detect 
the most prevalent DEL alleles in the donor population. It also involved the 
detection of 3 intact RHD alleles associated with an RhD negative phenotype 
– RHD(IVS8+1G>A), RHD(del343C) and RHD(IVS3+2T>A). This assay was 
further validated by testing against panels of 49 blinded samples.  
 
The third aim was to review the serologic profiles for a number of previously 
undescribed partial RhD and DEL phenotypes to investigate the reactivity and 
potential immunogenicity of these variants. 16 samples representing 11 
different alleles, including both DEL types and purported RhD negative 
variants were tested by adsorption and elution using a panel of monoclonal 
antibodies.  Of the samples tested, 15 were found to possess partial epitopes, 
with 2 alleles, the RHD(IVS8+1G>A) and RHD(IVS3+2T>A),  previously 
reported to be RhD negative.   
   
We conclude that the qPCR based RHD exon scanning and a targeted MGB 
qPCR can define the most prevalent DEL types in this donor population. In 
doing so, donations that can potentially cause life threatening transfusion 
reactions will be able to be readily categorised. We have also described a 
number of reactivity patterns for previously undescribed RHD variants. From 
this detection and categorisation, a transfusion strategy may be developed to 
decrease the potential risk to patients receiving blood transfusions and 
increase the overall safety of the donor panel in the Australian population  
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Chapter 1: Introduction 
Chapter 1: Introduction 
1.1 Overview 
 
There are currently 33 characterised blood group systems that consist of over 
300 different blood group antigens [27]. A blood group system is defined by the 
International Society of Blood Transfusion (ISBT) as one or more antigens 
present on the red blood cell (RBC) surface that are "controlled at a single 
gene locus or by two or more very closely linked homologous genes with little 
or no observable recombination between them” [27]. These antigens can be 
proteins, glycoproteins, glycolipids or carbohydrates, depending on the blood 
group system and are shown in Figure 1 [28].   
Of the 300 blood group 
antigens, around 50 occur 
frequently enough to be 
considered clinically 
significant due to their 
ability to induce the 
production of 
alloantibodies in patients 
that are transfused with 
mismatched donor RBCs 
or in pregnant women 
exposed to incompatible 
fetal RBCs [29-31]. It is 
important in transfusion 
medicine to ensure 
correct matching of donor 
and patient cells as these 
alloantibodies can lead to the destruction of donor cells with the 
corresponding antigens via haemolysis, i.e. an adverse haemolytic transfusion 
reaction [32].  Also, during pregnancy, if the fetus has RBC antigens that are 
not present in the mother, the production of maternal alloantibodies can occur, 
which attack the RBCs of the fetus. This can result in mild (anaemia and 
reticulocytosis) to severe (mental retardation and stillbirth), haemolytic 
disease of the fetus and newborn (HDFN) [32, 33].   
 
The Rh blood group system is the second most clinically significant after the 
ABO blood group system [34]. The RhD antigen is associated with delayed 
transfusion reactions in individuals with allo-anti-D, and remains the major 
cause of HDFN for RhD negative women who have been immunised by a 
previous pregnancy or transfusion. [34]. Prior to the 1968 introduction of anti-D 
immunoglobulin (Ig) prophylaxis of pregnant RhD negative women, HDFN 
was the leading cause of death in neonates [35, 36]. Universal administration of 
anti-D Ig to RhD negative women is recommended by the National Health and 
Medical Research Council (NHMRC), however the supply of anti-D Ig is 
dependent on donations of plasma from hyperimmune donors and Australia 
has only recently become self-sufficient [22]. 
 
To avoid RhD immunization by transfusion, all blood units for transfusion are 
serologically RhD phenotyped and RhD negative patients are transfused RhD 
Figure 1: Schematic representing clinically significant 
blood group antigens [7] 
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negative components. However, RBC donations with very weak expression of 
the RhD antigen (‘DEL’ donations) cannot be detected by automated 
agglutination based systems at the Australian Red Cross Blood Service 
(Blood Service). The laborious anti-D adsorption-elution and indirect 
antiglobulin test (IAT) that detects DEL phenotypes is not feasible for routine 
screening, and so DEL donations are currently typed and managed as RhD 
negative. Managing DEL donations as RhD negative is a contentious practice 
as despite low RhD antigen density, red cells from two DEL types, 
RHD(K409K) and RHD(IVS2-2A>G) have been implicated in primary and/or 
secondary immunization when transfused to RhD negative recipients[37-41].  
 
An alternative to DEL phenotyping is RHD genotyping. A quick and effective 
quantitative real time polymerase chain reaction (qPCR) molecular typing 
technique that screens for RHD exons 4, 5 and 10 is currently utilised by the 
Research and Development (R&D) Division of the Blood Service for 
determining fetal RHD status. However, this test is unable to distinguish 
between a number of RHD allele variants associated with RhD positive 
phenotypes, and those RHD alleles associated with RhD negative 
phenotypes. Outsourced single nucleotide polymorphism (SNP) analysis is 
required for further RHD allelic characterisation.  
 
The aim of this Masters project is to develop methods for detecting potentially 
immunogenic DEL donations by extending RHD exon mapping to all exons 
and including detection of RHD SNPs associated with DEL phenotypes to 
increase test resolution. This will allow for exact RHD allelic characterisation 
of the most frequent DEL alleles in the Australian RhD negative blood donor 
panel.  
 
Implementing routine, high resolution RHD genotyping as a method of DEL 
donor detection provides a reliable technique for stratifying DEL types based 
on risk level, which will be beneficial for transfusion management. Specifically, 
removing potentially immunogenic donations that are associated with an RhD 
positive phenotype from the RhD negative donation panel will increase the 
safety without unnecessarily removing donations that possess an RHD gene 
but are non-immunogenic from this valuable resource.  
1.1.1 Rh Blood Group System 
 
The RhD antigen is considered one of the most immunogenic and clinically 
significant RBC antigens due to the complete absence of the RhD antigen in 
predominantly all RhD negative individuals. The majority of alloantibodies 
potentially formed by the mismatch of donor/patient or mother/fetus RhD 
antigens (anti-D antibodies) are of the immunoglobulin G (IgG) isotype and 
can cause severe haemolytic transfusion reactions and HDFN in neonates [33]. 
 
In addition to the RhD antigen, the Rh blood grouping system also consists of 
the less clinically significant Rh antigens C, c, E and e antigens [42]. The RhD, 
RhC/c and RhE/e antigens are encoded by two genes within the RH locus; 
RHD and RHCE [43, 44]. The RHD gene encodes for the RhD antigen on the 
RhD protein and the RHCE gene encodes for the RhC, Rhc, RhE and Rhe 
antigens on the RhCcEe protein. Together, these antigens define the 
following phenotypes: Dce, ce, DCe, Ce, DcE, cE, DCE and CE [34].  Both the 
3 
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RHD and RHCE genes are 
comprised of 10 exons and are 
located antithetically tandem on 
chromosome 1p34-36 with 
coding regions that are 93.8% 
identical [45-47]. The high 
homology between the two RH 
genes results in the translated 
RhD and RhCcEe proteins 
differing by only 37 of 417 
encoded amino acids [13, 44]. Both 
RH genes are predicted to 
encode proteins consisting of 12 
transmembrane spanning 
domains with both the N and C-
terminus situated in the 
cytoplasm of the RBC, as shown 
in Figure 2 [48].  
 
This protein structure prediction 
is supported by the recently 
published crystal structure of a 
homologous protein; the RhC glycoprotein (RhCG) [49]. This protein was found 
to form a homotrimeric complex that is involved in ammonia transport and 
renal pH regulation. In addition to the RhD and RhCcEe proteins, a 
homologous gene named RHAG and found on chromosome 6, is involved in 
the expression of a similar protein, the Rh-associated glycoprotein [50]. The 
exact function of the RhAG protein is unclear; and whilst not shown to be 
immunogenic, it is believed to be involved in chaperoning the RhD and RhCE 
proteins to the cell membrane of the erythrocyte and can indirectly affect 
expression of the Rh antigens [48, 50]. Based on the RhCG structural model, it 
is believed that the RhAG , RhD and RhCcEe proteins form a heterotrimer 
complex, with speculation that it is involved in the transport of CO2, however 
debate about the function of this Rh complex is ongoing [49]. 
 
1.1.2 Molecular Basis of RhC, Rhc, RhE, Rhe and RhD negativity 
 
The RHc/RHC polymorphism is caused by six SNPs across exon 1 and 2 of 
the RHCE gene, with only the 307C>T SNP causing an amino acid change of 
Ser103 in the extracellular region of the protein. The RHe/RHE polymorphism 
is caused by a single SNP, 676G>C, in exon 5, which causes an amino acid 
change of Pro226 in the extracellular region of the protein[50]. In contrast, RhD 
negativity is most commonly caused by a complete deletion of the RHD gene 
but may also occur due to the presence of a variant RHD gene that does not 
express the RhD antigen [13, 50, 51].  
 
The majority of Caucasian (85%) and South East Asian (99%) individuals 
carry an RHD gene that encodes for the RhD antigen and are consequently 
RhD positive [8, 52-55]. As described above, the RhD negative phenotype is 
predominantly due to a complete deletion of the RHD gene [51, 56], however, an 
RhD negative individual can possess a variant RHD gene which encodes for 
Figure 2: A).  Diagram of the RHD and RHCE 
locus. The two RH genes have opposite 
orientation, with the 3′ends facing each other. Rh 
negative Caucasian individuals have a complete 
deletion of RHD. B). Rh proteins in the RBC 
membrane. Amino acid positions that differ 
between RhD and RhCE are shown as dark 
circles on RhD. The amino acid changes 
responsible for C/c and E/e polymorphisms are 
shown on RhCE.[13] 
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Figure 3: Relative antigen densities of RhD positive RBCs [1-6] 
very weak RhD protein expression that is below the detection limit of 
phenotyping platforms at Blood Banks [57]. For Caucasian populations, the 
RhD negative phenotype is largely due to deletion of the RHD gene [8], 
whereas in South East Asian populations, 15-30% of RhD negative individuals 
carry a RHD allele that encodes for very weak expression of the RhD protein - 
a DEL phenotype [52, 58]. 
1.1.3 RHD Gene Variants 
Normal RhD antigen density commonly ranges between approximately 
10,000-35,000 RhD sites/RBC for phenotypes in the increasing order: CcDee 
< ccDee < ccDEe < CCDee < ccDEE <  CcDEe [3, 6, 59]. Relative densities for 
the listed phenotypes are graphed in Figure 3. 
 
The RHD gene is 
highly polymorphic in 
nature, resulting in a 
number of RhD 
protein variants 
which possess a 
highly complex RhD 
antigen on the 
surface of RhD 
positive RBCs and/or 
differing RhD antigen 
densities. Molecular 
analysis has 
determined the 
genetic basis of 
many of these ‘D 
variants’. 
 
1.1.3.1 RHD-CE Gene Variants 
 
 
Due to the high homology 
and close proximity of the 
RHD and RHCE genes 
(Figure 4A), gene 
conversion events 
purported to occur in cis via 
a putative hairpin formation 
between the genes (Figure 
4B) can result in the 
substitution of RHD exons 
for RHCE exons (Figure 
4C) [8]. For reasons that 
remain unclear, RHCE is 
the donor and RHD is the 
acceptor in gene 
conversion events [60, 61]. 
Large RHCE substitutions 
 
Figure 4: Gene conversion events between RHD and 
RHCE at the RH loci occur via putative cis hairpin 
formation.[3, 8, 9] 
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can result in a complete lack of RhD antigen expression on the red cell 
surface, and so the RHD-CE hybrid allele is associated with an RhD negative 
phenotype (for example, alleles RHD-CE(3-7)-D, RHD-CE(4-7)-D and RHD-
CE(3-8/9)-D)[8, 62, 63]. Alternatively, gene conversion events can also result in 
hybrid RHD-CE alleles that express a RhD variant that lacks part of the RhD 
antigen epitope repertoire, specifically, known as ‘partial D’ variants (for 
example DIIIc, DV type 2 and DIV type 5)[64-66]. Transfusion of RBCs that 
express the complete repertoire of RhD antigen epitopes into patients with 
partial RhD positive blood can induce the production of anti-D antibodies 
against the RhD epitopes that the patient lacks, and thereby potentially cause 
a transfusion reaction [50]. 
1.1.3.2 Single Nucleotide RHD Gene Variants 
 
SNPs that give rise to nonsense, missense or frameshift insertion/deletions 
within the RHD gene can also have a number of effects on the RhD protein 
[51]. SNPs in the RHD gene that encode amino acid changes within the 
intracellular or transmembrane regions of the RhD protein can result in 
weakened expression of the RhD antigen and are referred to as ‘weak D’ 
variants [67].  Weak D variants typically possess the complete repertoire of 
RhD antigen epitopes but show a decrease in RhD antigen density on the cell 
surface and hence a weakened antigenicity [34]. SNPs that result in amino acid 
changes within extracellular loops of the RhD protein can change the RhD 
epitope and cause the aforementioned partial D variant. It is important to note 
that weak and partial D variants are not mutually exclusive. Some RhD 
variants show a combination of both qualities, expressing both a partial RhD 
epitope repertoire that is also very low in RhD antigen density. It has also 
been observed that SNPs within the RHD gene can cause a complete lack of 
antigen expression [9], thereby causing the donation to be non-immunogenic 
and safe for inclusion in the RhD negative donation panel.  
 
For RHD variants, whether they encode for a partial RhD epitope and/or 
weaken RhD antigen levels, RhD antigen density can occur within a normal 
range of 10-35,000 RhD sites per RBC (including DIVa, DHMii and DIIIc), 
reduced to <10,000 RhD sites per RBC or as few as only several hundred 
RhD sites/RBC (including DVa, DVIa, DVII, DNU and weak D type 1, 2, 3) [4, 61, 
68], as shown in Table 1 below. 
 
Table 1. RHD variants and their respective phenotypes and antigen density 
RhD variant RHD allele Amino acid 
change 
within RhD 
protein 
region 
RhD Phenotype Antigen 
Density 
Reference 
R1r CcDee N/A RhD positive 9000-
15000 
[6, 68] 
DVII 329 T>C Leu110Pro Weak/partial 2400-
9500 
[4, 69] 
Weak D type 3 8C>G Ser3Cys Weak 1800-
3000 
[69] 
Weak D type 11 885G>T Met295Ile DEL/Weak D <22-57 [41, 70] 
K409K 1227G>A Lys409Lys DEL <22 [70] 
 
6 
Chapter 1: Introduction 
 
Figure 5: Proposed position of RhD epitopes 
relative to extracellular  loops [12] 
Due to the complexity of the RhD epitope, multiple anti-D antibodies with 
different specificities and afffinities have been characterised. Lomas et al first 
proposed in 1993 that there were 9 reactivity patterns of monoclonal anti-D 
antibodies [71]. A study in 1996 by Scott et al incorporated testing of a variety 
of RhD variant phenotype donations against 168 MoAbs and subsequently 
defined over 30 different RhD reactivity patterns [12]. A proposed structure was 
presented by Scott et al as shown in Figure 5.  
 
 Due to the variability 
described, the RhD antigen 
presents a special 
phenotyping challenge for 
Blood Banks. Currently, 
partial RhD and weak RhD 
expression is detected by 
routine blood bank testing 
with the use of anti-D 
monoclonal blends and 
sensitive serological testing 
procedures. From a genetic 
molecular testing point of 
view it is important to distinguish between the RHD alleles that express 
potentially immunogenic RhD positive variants and those RHD alleles that are 
associated with the RhD negative phenotype. The latter being either hybrid 
RHD-CE alleles with large RHCE substitutions and RHD alleles comprising 
SNPs that do not encode for RhD protein and thus can be safely managed as 
RhD negative as they pose no risk of RhD immunisation. 
1.1.4 DEL Phenotypes 
 
Some blood donors express an RhD antigen so weak that it is below the 
detection limit of serological screening platforms at Blood Banks, and have 
been coined ‘DEL’ donors. The term DEL is derived from the manual anti-D 
adsorption-elution then indirect antiglobulin test on the eluate that is able to 
correctly assign DEL phenotypes as very weakly RhD positive [57]. As 
described above, normal RhD positive RBCs express between 10,000 – 
35,000 RhD antigens/cell [3, 6, 59], whereas DEL RBCs have been reported to 
express as few as 20-40 RhD antigens/cell [4, 61, 68, 70]. Due to the significantly 
reduced RhD antigen density/RBC, donations with a DEL phenotype are 
missed during routine agglutination based testing, and as it is not practicable 
to routinely screen for DEL using the test described, DEL donors are typed 
and managed as RhD negative. Typing DEL donations as RhD negative is a 
controversial practice, as DEL blood units have been reported to alloimmunise 
RhD negative transfusion recipients [38, 39, 41, 72].  
 
Previous studies have revealed that the DEL phenotype is associated with 
RhC and/or RhE positive phenotypes (also known as r’r and/or 
r”r,respectively) [41, 73]. Considering this, many DEL prevalence studies have 
focused on this subgroup of the RhD negative donor panel. The prevalence of 
DEL alleles in East Asian r’r and/or r”r blood donors has been reported to be 
as high as 15-30% with the RHD(1227G>A) (also referred to as RHD(K409K)) 
DEL allele observed most frequently [53-55, 57, 74]. In Caucasian populations, 
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RHD(IVS3+1G>A) and RHD(885G>T) (also referred to as RHD(M295I)) are 
the most frequent DEL alleles, however the prevalence is reported to be 
between 1-2% within the r’r and/or r”r blood donor subgroup [73, 75].  
 
To date, 17 RHD alleles that encode for DEL phenotypes have been 
characterised [9, 76]. Data collected by the Blood Service has revealed a variety 
of DEL alleles are present within the r’r and/or r”r blood donor panel at a 
prevalence of 2.17% (95% CI: 1.54-2.81%) or 44/2,027 r’r and/or r”r blood 
donors screened. Of these 44 DEL samples, the most common was the 
RHD(K409K) DEL allele (n=16), representing 0.79% of the r’r and/or r”r blood 
donor subgroup [77]. There are approximately 5,000 r’r and/or r”r donors 
currently registered in Australia. Using a 2.17% DEL prevalence rate, we 
estimate 109/5,000 of these donors have will carry a DEL associated RHD 
allele. Based on 109 DEL donors donating four times a year, as many as 436 
potentially immunogenic DEL donations are issued as RhD negative every 
year in Australia. 
 
The prevalence of the RHD(K409K) DEL is consistent with an increasing 
number of Australian residents declaring themselves of Asian ancestry. 
Specifically, the percentage of respondents declaring themselves of Asian 
ancestry increased from approximately 7% in the 2006 national census to 
approximately 12% in the 2011 national census [78]. The finding is significant 
as red cells from RHD(K409K) DEL donors have been reported to cause 
primary and secondary isoimmunisation within RhD negative transfusion 
recipients [38, 41]. 
 
The manual anti-D adsorption-elution/indirect antiglobulin serological test 
used to correctly type DEL donors as RhD positive is laborious in nature, so 
not feasible for routine screening. Alternatively, to avoid unnecessary risk of  
RhD immunisation by DEL transfusion, the German Red Cross (DRK) Blood 
Donor Service in Baden-Württemberg, Germany and Aarhus University 
Hospital in Denmark identify and subsequently remove DEL donors from the 
RhD negative donor panel using a RHD genotyping test [73, 75]. Notably, the 
RHD genotyping test described by Flegel and colleagues has been tailored to 
local RHD alleles, and has been in use since 2002 [79]. 
 
Many review articles have addressed the introduction of molecular genotyping 
techniques as a means of identifying RHD variants. The recommendations of 
the authors vary, from across the board genotyping of all donations [80, 81] to 
the introduction of molecular testing for weak RhDs 1-3 [82], or as a 
compliment to the current serological process [83]. However, the resounding 
consensus of recent review articles is that molecular genotyping is a crucial 
tool in the identification of different blood groups, especially for the detection 
of RHD variants. This project is in full concordance with that opinion and aims 
to develop a genotyping method appropriate for the Blood Service. 
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Figure 6: Mechanism of fluorescence of dual 
labelled qPCR probes. 
1.2 Review of Current Genotyping Techniques 
1.2.1 RHD Genotyping of RhD Negative Blood Donors: Methods 
Used Globally 
 
A variety of genetic techniques are currently used worldwide to detect the 
presence of RHD variants. The commonly used techniques are:  
a) Conventional Site Specific Polymerase Chain Reaction (SS-PCR) usually 
followed by Sanger sequencing of DNA amplicons 
b) Quantitative Polymerase Chain Reaction (qPCR)  
c) High Resolution Melt (HRM).  
 
Conventional SS-PCR: 
PCR is a widely used technique that involves the amplification of a target DNA 
sequence via a heat stable polymerase (usually Taq polymerase) that 
enzymatically assembles new double stranded DNA (dsDNA) using free 
nucleotides. This is done via thermal cycling, in which a dsDNA template is 
heated to melting point to separate the sense and anti-sense strands, after 
which the temperature is lowered to annealing and extension temperature to 
allow the single stranded (ssDNA) oligonucleotide sequences (primers) to 
attach to the template and begin amplification. This process is repeated 
across a number of cycles and the product can then be visualised via 
electrophoresis on agarose gel.  
 
qPCR: 
qPCR is a second generation PCR technique that is based on the same 
principles as conventional PCR but allows simultaneous detection and 
quantification of DNA using one 
of two methods: non-specific 
fluorescent dyes that intercalate 
in the presence of any dsDNA, or 
fluorescently labelled sequence 
specific oligonucleotides. Both 
methods involve specific forward 
and reverse primers, a heat 
stable polymerase and free 
nucleotides, however the thermal 
cycler used in qPCR has the 
ability to emit light and excite the 
fluorochrome or fluorescent dye, 
causing it to emit fluorescence at 
the relative wavelength. This 
emission is then detected to allow 
the DNA amplification to be 
viewed as the reaction 
progresses (or ‘real time’).  
 
The first method utilises a DNA 
binding dye (e.g. SYBR green) 
that is present in the assay but 
only emits fluorescence after 
binding to dsDNA. The amount of 
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Figure 7: Homozygous wild type, mutation and heterozygote samples are shown on a standard normalized 
melt curve (A) and a difference plot normalized to mutant samples (B).[10] 
fluorescence is measured after each cycle, allowing for the concentration of 
amplified DNA to be measured. This method is not without constraint, as all 
dsDNA in the reaction will fluoresce, which may lead to interference from non-
specific PCR products. It also lacks the ability of multiplex reactions as it is not 
possible to distinguish between different amplification products.  
 
The second qPCR method involves a dual labelled oligonucleotide (probe) 
that is conjugated with a fluorochrome on the 5’ end of the oligonucleotide and 
hybridize to an internal region of a PCR product. A quencher present on the 3’ 
end of the oligonucleotide inhibits emission via fluorescence resonance 
energy transfer (FRET) due to the close proximity to the fluorochrome. When 
the probe is bound to the single stranded DNA (ssDNA) template and then 
subsequently cleaved by the polymerase, emission occurs and can be 
detected in real time [84, 85].  
 
HRM: 
HRM is carried out on the amplified product produced from a prior PCR assay. 
It involves the use of intercalating dyes that fluoresce when bound to the 
double-stranded DNA of the target sequence. The dsDNA is then heated to 
separate the DNA strands and the fluorescence decreases giving a visible 
melting curve. Due to the difference in binding temperatures of different base 
pairs, this curve will differ depending on the base pairs present in the DNA, 
allowing the detection of a single SNP [86, 87]. 
A number of European countries, including France, Austria, Germany, 
Switzerland and Denmark have implemented some form of routine molecular 
genetic testing strategy [72, 73, 75, 88, 89] and in Switzerland, the serological IAT 
has been dropped and a PCR strategy has become mandatory [90]. In addition 
to the change of protocol in Switzerland, routine molecular genetic testing, 
incorporating RHD specific PCR and DNA Sanger sequencing to screen for 
RHD positive donors in the RhD negative panel, has been implemented at the 
German Red Cross (DRK) since 2002. This has resulted in many DEL RBCs 
being correctly typed as very weak RhD positive, thereby reducing the risk of 
RhD immunisation in RhD negative transfusion recipients [75]. Specifically, 
Flegel and colleagues used methods which involved screening for a RHD-
specific polymorphism in intron 4 in all first time RhD negative donations via 
PCR and agarose gel analysis, followed by Sanger sequencing of samples 
identified as RHD intron 4 positive. Since the implementation of this RHD 
specific PCR and DNA Sanger sequencing technique, many DEL screening 
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studies around the world have used similar techniques to detect DEL 
associated RHD alleles within the RhD negative blood donor panel [52, 73, 74, 89, 
91-95].  
A recent Danish study involving RHD screening via qPCR of exons 5, 7 and 
10 with subsequent sequencing for detection of DEL alleles concluded that 
due to a prevalence of 0.26% in the RhD negative panel, a routine molecular 
test was not necessary [37].An RHD specific PCR technique that incorporated 
a qPCR melting curve analysis was utilised by a Taiwanese study to detect 
the RHD(K409K) allele only [96].  
 
Another recent study carried out in the Netherlands involved multiplex ligation-
dependant probe amplification (MLPA)[97]. Whilst this study was able to detect 
the presence and zygosity of RHD alleles, it involves a cumbersome 16 hour 
hybridisation step and can assess a total of only 16 samples concurrently. 
This technique would not be applicable for the high throughput routine testing 
environment of the Blood Service.  
1.2.2 RHD Genotyping of RhD Negative Blood Donors: Methods 
used at the Blood Service 
 
There is currently no routine molecular testing in use at the Blood Service to 
detect RHD positive donors within the RhD negative blood donor panel. 
However, the Blood Service has offered a clinical referral program for the 
determination of fetal RHD status via genotyping for 15 years. Until recently 
this genotyping was only possible via amniocentesis; an invasive procedure 
which carries many risks to the pregnancy and may trigger an immunising 
event leading to the production of maternal antibodies [56, 98]. This genotyping 
procedure involves the detection of exons 4 and 7 of both the RHD and 
RHCcEe gene via conventional PCR. The assay includes a universal forward 
primer for both genes and two separate reverse primers; one specific to RHD 
and another that is specific to the RHCcEe gene and is 5bp further 
downstream. This allows the visualisation of the different sized bands on 
agarose gel following electrophoresis. Using the Bio-Rad Image Lab software, 
the DNA amplicon concentration in the band can be analysed to determine the 
RHD:RHCcEe ratio and therefore zygosity. This assay is crude and has a 
number of drawbacks, including a high propensity for contamination due to the 
nature of conventional PCR; low throughput analysis; and the inability to 
detect RHD variant alleles, leading to the possibility of both false negative and 
false positive results.  
 
The discovery of free fetal DNA (ffDNA) in 1997 [67, 99] has allowed for the 
development of a non-invasive prenatal screening process. The Blood Service 
has adapted a qPCR assay that is modelled on a testing service established 
by Finning et al in the UK and detects exons 4, 5 and 10 of the RHD gene [11, 
100]. The test is used to predict the RhD status of the fetus in RhD negative 
women via detection of cell-free fetal RHD in maternal plasma.   
 
A current Blood Service DEL prevalence research project has also 
successfully expanded on this NIPA qPCR technique to detect RHD variants 
within the RhD negative donor panel. Considering RHD variants in the RhD 
negative blood donor panel are predominantly associated with the the RhD 
negative, RhC and/or RhE positive phenotypes, it is within this defined donor 
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subgroup that the for-research-only molecular testing is carried out in order to 
maximise detection of any functional RHD variants. 
 
Whilst the current method of qPCR testing using RHD exons 4, 5 and 10 is 
sensitive and RHD specific, it cannot call the RHD allele in the event of a RHD 
variant (low resolution genotyping). In the event of qPCR positivity for RHD 
exon 4, 5 or 10, an unresolved result is obtained, and the samples are 
outsourced to Progenika in Spain for further BLOODchip™ SNP based DNA 
microarray analysis. From these SNP microarray results, the exact DEL allele 
that is present can be determined. This offshore CE accredited analysis has a 
number of drawbacks; 1) high cost; 2) poor timeliness of results (genotyping 
data is often not received for weeks); 3) 5-10% of genomic DNA (gDNA) 
samples remain unresolved as SNP based DNA microarray platforms 
incorporate known polymorphisms only; and 4) a risk of inaccuracy as several 
reporting mistakes have been made by Progenika. 
1.2.3 Current RhD Epitope Profiling 
 
The RhesusBase database is an online compilation of published information 
on the molecular variability observed at the RHD locus [9]. The list of DEL 
associated RHD alleles on this database is by no means comprehensive or 
definitive and the serological analysis of RBCs derived from DEL donors is 
ongoing research. Hence, the immunising potential of many DEL alleles is not 
currently known – i.e. whether the DEL alleles express the full repertoire of 
RhD epitopes (epD), or a partial RhD antigen. Anti-D reactivity against RBCs 
derived from donors carrying DEL alleles: RHD(IVS3+1G>A), RHD(K409K), 
RHD(IVS5-38del4), RHD(X418) and RHD(M295I) [70, 89] has been previously 
described.  
 
The RHD(IVS3+1G>A) DEL allele was found to lack epDs of the Rh antigen 
mosaic with only epitopes 2.1 and 5.4 being detected by anti-D MoAbs 
P3x249 and P3x241 respectively [70]. It was also found to exhibit a weaker 
expression of the RhD antigen on the red cell surface, hence classifying this 
RHD allele as both a partial and DEL phenotype. A similar study was 
completed on the RHD(IVS5-38del4) allele [41] and on a range of partial and 
weak D variants [22, 101]. It has been previously determined that the 
RHD(IVS3+1G>A) DEL allele lacks part of the RhD antigen  mosaic, whereas 
DEL alleles RHD(K409K),  RHD(IVS5-38del4),  RHD(X418) and 
RHD(885G>T) possess a full epitope profile [70, 90]. 
 
A number of RHD alleles have as yet undescribed serological reaction 
patterns, including but not limited to alleles RHD(IVS3+2T>A), RHD(94insT) 
and RHD(IVS1+1G>A). There are also two novel alleles; RHD(IVS2-2delA) 
and RHD(IVS1+5G>C), not previously described in literature that were found 
to be present in the Australian population in the previous pilot study at the 
Blood Service. The serological profiles of these alleles are not currently 
known. The Blood Service currently classifies all these RHD variants as RhD 
negative and may be transfused to RhD negative patients. Therefore it is 
paramount to test the reactivity profiles of these RBCs against a range of 
MoAbs in order to determine their immunising potential. 
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1.3 Aims and Objectives of this Study 
 
Hypothesis:  The diagnostic accuracy of detecting genotypic variants 
of RHD negative blood can be improved by the extended exon mapping and 
subsequent SNP genotyping of the RHD gene in donors. The extended 
serological testing will increase our knowledge pertaining to the potential 
immunogenicity of a number of RhD variants thus providing a valuable 
supportive role in pretransfusion testing of RhD negative blood units.   
 
Aim 1: Extend RHD exon mapping via a qPCR method that can 
discriminate between the 10 exons of the RHD gene and the closely 
homologous RHCE gene. The results of the amplification of these genes will 
allow for the removal from the RhD positive donor panel of RHD-CE hybrid 
alleles that comprise of large RHCE exon substitutions and are therefore 
associated with an RhD negative phenotype. 
Aim 2: Develop a specific qPCR genotyping method to test for 
common RHD SNPs associated with the RhD negative phenotype and the 
most common DEL phenotypes in the Australian population. This will be 
achieved by designing and testing primers and Minor Groove Binding (MGB) 
probes that discriminate between wildtype RHD alleles and RHD alleles 
possessing SNP changes. These variations can then be used in the creation 
of an algorithm for further routine blood typing to keep RHD alleles not 
reported to be immunogenic in the RhD negative panel and place DEL types 
reported to be immunogenic correctly in the RhD positive panel.   
Aim 3: Map the anti-D reactivity of RBCs derived from RHD variants 
with as yet undescribed serological reaction patterns, including but not limited 
to; RHD(IVS3+2T>A), RHD(94insT), RHD(IVS2-2delA), and 
RHD(IVS1+1G>A), via their reactivity against D-SCREEN monoclonal anti-D 
antibodies. This test will determine whether the D-SCREEN anti-Ds have the 
same pattern of reaction with the said DEL alleles as with normal RhD positive 
RBCs. If not, this will suggest that these DEL alleles lack part of the RhD 
antigen mosaic. 
1.4 Thesis Outline 
 
This thesis will be broken up into 3 remaining chapters. Chapter 2 will detail 
the research design, including the materials and methods used, design of 
primers and probes, the sample preparation, qPCR optimisation and 
multiplexing procedure, followed by the epitope mapping of aim 3 and finally 
the validation procedure. Chapter 3 will outline the results obtained and will be 
in 4 sections: Aim 1 results, aim 2 results, the validation results of aim 1 and 2 
and lastly the aim 3 results. Chapter 4 provides a discussion of results, 
limitations and future research for each separate aim, and a final project 
overview and conclusion.  
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1.5 Study Design 
 
  
Using qPCR, distinguish which RHD exons are present 
Aim 2: Design primers and MGB probes around frequent DEL associated SNPs 
Aim 1: Design 10 primers/probes for exons 1-10 of the RHD gene. 
Samples negative 
for all exons kept 
in RhD negative 
panel of donations 
Samples positive 
for all exons will be 
tested for DEL 
alleles 
Using qPCR, distinguish between presence of 
known frequent DEL alleles or no presence 
All results will be validated against 
SNP data already acquired 
Positive samples placed 
in RhD positive panel of 
donations 
Negative samples typed for 
RHc/C RHe/E  
RHce samples kept in RhD 
negative panel of donations 
C or E positive samples kept 
for testing 
All samples are serologically typed for 
RhD 
Total donor panel 
Non functional 
hybrid alleles kept 
in RhD negative 
panel of donations 
Functional hybrid 
alleles will be 
identified and 
suggested for removal 
from RhD negative 
panel 
Samples positive for DEL alleles 
will be suggested for removal from 
RhD negative panel of donations 
Samples negative for DEL 
alleles will require further 
testing for classification 
Aim 3: Extend serological testing of RHD variant samples 
Compare results to current literature where possible 
Samples with no 
reactivity against 
DSCREEN antibodies 
kept in RhD negative 
panel of donations 
Samples with reactivity 
against DSCREEN 
antibodies suggested 
for removal from RhD 
negative panel of 
donations 
Contribution of new knowledge 
Routinely 
performed by 
Blood Service 
Performed by Dr 
Scott as part of 
the previous 
population 
screening project 
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Chapter 2: Research Design 
2.1 Ethics 
As this project involves the use of human blood samples, ethics approval was 
obtained from the Australian Human Research Ethics Committee (HREC) 
under the approval code 2011#06. The project name is “To assess the 
capacity of RHD genotyping and flow cytometry to identify DEL variants within 
the Australian RhD(neg), C and/or E(pos) blood donor population”. The chief 
investigator is Associate Professor Catherine Hyland.  
 
Previous ethics approval for this project fell under HREC approval 2010#7, 
“Blood group molecular typing for donors and patients: a population study for 
RHD and other blood group molecular variants”. 
 
2.2 Sample Preparation 
Ethylenediaminetetraacetate (EDTA) blood samples (6 ml) from volunteer 
blood donors were retrieved after mandatory viral serology testing from Blood 
Service Processing Centres. Samples were selected on the basis that the 
phenotype was RhD negative, RhC and/or RhE positive. Samples were 
collected between March 2011 and December 2012 by Dr Stacy Scott.  
 
Genomic DNA (gDNA) from blood samples was isolated from whole blood or 
buffy coat using the EZ1 DNA Blood 350µl kit (Qiagen) and gDNA 
concentration and purity was assessed using a NanoDrop 2000c 
spectrophotometer (Thermo Scientific). 
2.3 Extended RHD Exon Mapping 
Previous studies have established that the RhD negative, RhC and/or RhE 
positive donor panel contains the highest prevalence of incorrectly classified 
RhD positive RBCs [41, 73]. Previous research performed at the Blood Service 
estimated the prevalence of RHD-CE variants in the Australian RhD negative, 
RhC and/or RhE positive blood donor panel to be 5.18% (105/2027) using the 
aforementioned RHD exon 4, 5,10 qPCR assay and BLOODchip™ SNP array 
analysis. The BLOODchip™ SNP based array platform determined 101/2,207 
samples positive for RHD exon 10 only were RHD-CE hybrids (Table 2). In 
addition, four samples positive for RHD exons 4, 5, and 10 were RHD-CE 
hybrid alleles: RHD(9:del/CE), RHCE(1-3)-D(4-10) and RHD(8:del/CE) 
represented twice (Table 2).  
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Table 2: RHD-CE hybrids detected in RhD negative r’r & r”r subgroups. 
 
 
RHD allelic description 
(N: RHD allele) 
 
Predicted phenotype 
[Reference] 
  
RHD exon 10 positive 
80: RHD-CE(3-8/9)-D RhD negative[102, 103] 
9: RHD-CE(3-7)-D linked to RHCEceS† RhD negative[103] 
4: RHD-CE(4-7)-D RhD negative[8] 
4: RHD-CE(4-9)-D RhD negative/DEL[94, 104] 
1: RHD-CE(2-7)-D RhD negative[8, 23, 105]   
1: RHD-CE(2-8)-D RhD negative[8, 23, 105]  
1: RHD-CE(2-9)-D RhD negative[8, 23, 105] 
1: RHD-CE(3-7)-D RhD negative[8, 106] 
RHD exon 4, 5 & 10 
positive 
1: 
1: 
2: 
RHCE(1-3)-D(4-10) 
RHD(9:del/CE)* 
RHD(8:del/CE)* 
RhD negative[14] 
Unknown 
Unknown 
† Often referred to as the r’S phenotype.[107] 
* del/CE refers to either a deletion of the RHD gene or substitution of the RHCE gene 
 
Using the current qPCR test only, it is impossible to obtain detailed allelic 
information about these RHD positive donations and BLOODchip™ testing is 
required by offshore provider Progenika to determine the exact RHD allele 
present. In addition, further Sanger sequencing analysis was required for a 
number of samples as Progenika’s SNP profiling returned a ‘NO CALL’ or 
‘Apparently Non-Negative’ result. As such, the design of a qPCR assay that is 
able to detect all of the RHD exons is needed, in order to determine the exact 
RHD-CE hybrid allele present without the need for outsourcing. The majority 
of these RHD positive hybrids have been determined to be RhD negative (as 
shown by the predicted phenotype column in Table 2) and if correctly 
genotyped can be released into the valuable RhD negative donor panel.  
 
Primer and probe sets for RHD exons 4,5,7 and 10 and the internal positive  
are already in use at the Blood Service for the aforementioned NIPA and DEL 
population studies (Section 1.2.2) and sequences are listed in Table 3.  
 
The remaining RHD exons that require the design of primers and probes are 
exon 1,2,3,6,8 and 9. As the RHD and RHCE genes are so similar, the first 
step in designing primers and probes to identify the ten RHD exons was to 
align the two gene sequences. Genbank accession number BN000065.1 was 
utilised and exon 3 RHD and RHCE alignment is show in Figure 7 as an 
example.  
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Upon alignment the first notable comparison of the RHD/RHCE genes was 
that exon 1 and exon 8 of RHD gene are identical to the corresponding exons 
of the RHCE gene. There were also no intronic mismatched SNPs within an 
acceptable range of RHD exons 1 and 8 that would enable qPCR analysis. 
This unfortunately meant that there was no way to differentiate between RHD 
and RHCE exon 1 and 8 via qPCR. 
 
Current literature was searched for primers/probes already in use that could 
be utilised in this study. Primer sets have been described for RHD exon 1 [108],  
2 [53], 3, 6, 9 [109], and 8 [110]. Unfortunately these primers were designed for 
use with conventional PCR and as such the resultant amplicon is either too 
large for qPCR assays (>150bp) or the length of template nucleotide 
sequence between forward primer and probe is too long (> 20bp). As such, 
the remaining exons that required primer and probe design were exon 2, 3, 6, 
and 9.  
 
For RHD exons 2, 3, 6 and 9, design of primers and probes was aimed 
around the SNP differences between the RHD and RHCE genes and following 
accepted qPCR design protocol. Specifications for primer design:  
amplification product < 150bp; primer Tm approximately 5°C greater than 
annealing temperature; temperature difference between forward and reverse 
primers ≤3.0°C; G/C clamp at the 3’ end of primers (where possible); primer 
length > 17bp; avoid self-complementarity between forward and reverse 
primers; GC content 30-80% where possible. For probe design: no G base at 
the 5’ end (as guanine is an effective quencher of fluorescence); less than 
40bp length; GC content 30-80% where possible, Tm 10°C greater than primer 
Tm; designed as close to the primers without overlapping; mismatched bases 
in the centre of the probe.   Where possible, exonic regions were preferential, 
however some intronic regions were required to be used, either due to the 
lack of SNPs or the presence of other SNPs that affect different blood group 
antigens (such as RHC/c SNPs described in section 1.1.2).  
 
Primer Tms were aimed at 64°C, 5°C above the current annealing temperature 
of 59°C in use for other research projects and NIPA testing. Primers were 
 
Figure 8: Alignment of RHD and RHCE genes, exon 3 (highlighted in teal) and flanking 
intronic nucleotides. Highlighted red base pairs indicate SNPs, primer and probe sequences 
in bold italic.  
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then ordered from Sigma Aldrich in a liquid form at an 800µM concentration. 
TaqMan® hydrolysis probes were ordered from Applied Biosystems at a 
100µM concentration. Initially, VIC and FAM fluorochromes were ordered for 
the probes. After initial specificity testing of the first primer and probe sets 
listed in Table 4 (see results section 3.1). A number of primers and probes 
were required to be redesigned. The same design process was applied and 
these sequences are listed in Table 5 and Table 6.  
 
 
 
Table 3: Primers and probes already in use for research at ARCBS. 
 
Exon Sequence Tm
(°C) 
Length Amplicon 
size 
Reference
Exon 4   
Forward 5’ – CTG CCA AAG CCT CTA CAC 
G– 3’ 
 
63.6 19bp 
71bp 
Amplicon 
Product 
[11] 
Reverse 5’ – ATG GCA GAC AAA CTG GGT 
GTC – 3’ 
66.2 21bp [11] 
Probe 5’ – [6FAM] TCT GGC CAA  GTT  TCA  
ACT CTG CTC GCT [TAMRA] – 3’ 
75.6 27bp [11] 
Exon 5   
Forward 5’ – cGC CCT CTT CTT GTG GAT G – 
3’ 
65.8 19bp 
82bp 
Amplicon 
Product 
[11] 
Reverse 5’ – GAA AGG AAG AAT GCC GTG 
TTC – 3’   
64.6 21bp [11] 
Probe 5’ – [6FAM] TCT GGC CAA GTT TCA 
ACT CTG CTC TGC T [TAMRA]  - 3’  
74.6 28bp [11] 
Exon 7    
Forward 5’ – GGG TGT TGT AAC CGA GTG 
CTG – 3’ 
66.6 21bp 
125bp 
Amplicon 
product 
[18, 19] 
Reverse 5’ – CCG GCT CCG ACG GTA TC – 3’ 66.8 17bp [18, 19] 
Probe 5’ – [6FAM] CCC ACA GCT CCA TCA 
TGG GCT ACA A [TAMRA] – 3’ 
75.1 25bp [19] 
Exon 10    
Forward 5’ – CCT CTC ACT GTT GCC TGC 
ATT – 3’  
66.5 21bp 
73bp 
Amplicon 
Product 
[20] 
Reverse 5’ – AGT GCC TGC GCG AAC ATT – 
3’   
67.0 18bp [20] 
Probe 5’ – [VIC] TAC GTG AGA AAC GCT 
CAT GAC AGC AAA GTC T [TAMRA] 
– 3’ 
74.6 31bp [20] 
Exon CCR5 
Forward 5’ – TAC CTG CTC AAC CTG GCC 
AT – 3’ 
66.8 20bp 
91bp 
Amplicon 
Product 
[11] 
Reverse 5’ – TTC CAA AGT CCC ACT GGG C 
– 3’ 
67.3 19bp [11] 
Probe 5’ – [VIC] TTT CCT TCT TAC TGT 
CCC CTT CTG GGC TC[TAMRA] – 3’ 
74.1 29bp [11] 
Upper case denotes exonic region 
Lower case denotes intronic region 
Underline denotes introduced mismatches 
Bold red denotes discrepancies between RHCE and RHD gene 
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Table 4: First set of primers and probes designed for extended RHD exon mapping 
 
Exon Sequence Tm (°C) Length Amplicon 
size 
Exon 2 
Forward 5’ – gtc tgc ttc ccc cac g – 3’ 63.1 16bp 
63bp 
Amplicon 
Product 
Reverse 5’ – ACG GTC AGA TCT TGG CCA – 3’ 64.5 18bp 
Probe 5’ –[VIC] ctc gcc atc tcc cca ccg agc 
[TAMRA] – 3’ 
76.2 21bp 
Exon 3 
Forward 5’ – tcc ccc agT ATT CGG CTG – 3’ 66 18bp 
71bp 
Amplicon 
product 
Reverse 5’ – TTC CCC AAG ACA GCA TCC A – 3’ 66.8 19bp 
Probe 5’ – [6FAM] CAT GAG TGC TTT GTC GGT 
GCT G [TAMRA]  - 3’ 
70.1 22bp 
Exon 6 
Forward 5’ – TGG CTG GGC TGA TCT ACG – 3’ 65.1 18bp 
80bp 
Amplicon 
product 
Reverse 5’ – tca gcc aaa gca gag gag g – 3’  65.6 19bp 
Probe 5’ – [VIC] tac CGG CAG GTA CTT GGC 
TCC [TAMRA] – 3’ 
69.6 21bp 
Exon 9 
Forward 5’ – aaa tta tgc att taa aca gGT TTG  – 3’ 59.8 24bp 
81bp 
Amplicon 
Product 
Reverse 5 – TTG GTC ATC AAA ATA TTT AGC CT – 
3’ 
60.3 23bp 
Probe 5’ – [VIC] TCC TAA ATC TTA AAA TAT 
GGA AAG CAC [TAMRA] – 3’
62.3 27bp 
Upper case denotes exonic region 
Lower case denotes intronic region 
Underline denotes introduced mismatches 
Bold red denotes discrepancies between RHCE and RHD gene 
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As it proved considerable difficult to achieve RHD specificity for exon 9, 7 new 
forward primers, a new reverse primer and a new probe were designed and 
are listed in Table 6. 
 
 
Table 5: Second set of primers and probes designed for extended RHD exon mapping 
 
Exon Sequence Tm 
(°C) 
Length Amplicon 
size 
Exon 2 
74bp 
amplicon 
product 
Forward 5’ – GAC CGT GAT GGC GGC TA – 3’ 66.2 17bp 
Reverse 5’ – AGG CCA CAC TGC TCC AGC – 3’ 66.9 18bp 
Probe 5’ – [VIC] CTT CCT CAC CTC GAG TTT CCG 
GAG ACA C [TAMRA] – 3’ 
75.4 21bp 
Exon 2b 
63bp 
amplicon 
product 
Forward 5’ – gtc tgc ttc ccc cac g – 3’ 63.2 16bp 
Reverse 5’ – ACG GTC AGA TCT TGG CCA – 3’ 64.5 18bp 
Probe 5’ –[VIC] ctc gcc atc tcc cca ccg agc [TAMRA] 
– 3’ 
76.2 21bp 
Exon 6 
80bp 
amplicon 
product 
Forward 5’ – TGG CTG GGC TGA TCT ACG – 3’ 65.2 18bp 
Reverse 5’ – tca gcc aaa gca gag gag g – 3’  65.7 19bp 
Probe (on antisense) 5’ – [VIC] tac CGG CAG GTA 
CTT GGC TCC [TAMRA]  – 3’ 
69.2 21bp 
Exon 9 
95bp 
amplicon 
product 
Forward 5’ – tta aat tat gca ttt aaa cag GTT TGC – 3’ 63.5 27 
Reverse 5’ – CTT CCA GAA AAC TTG GTC ATC AAA 
– 3’ 
65.0 24 
Probe 5’ – [6FAM] CCT AAA TCC TAA AAT ATG 
GAA AGC ACC TCA TGA CGC  [TAMRA]  – 
3’  
75.2 36 
Upper case denotes exonic region 
Lower case denotes intronic region 
Underline denotes introduced mismatches 
Bold red denotes discrepancies between RHCE and RHD gene 
Table 6: Second set of primers  and probedesigned for extended RHD exon mapping – exon 9 only
 
Exon Sequence Tm 
(°C) 
Length
Exon 9 
Forward #1 5’ – aga tta aaa atc ctg tgc tcc aaa c – 3’ 64.1 25bp 
Forward #2 5’ – aga tta aaa atc ctg tgc tcc aat c – 3’ 64.1 25bp 
Forward #3 5’ – att aaa aat cct gtg ctc caa gc – 3’ 64.1 23bp 
Forward #4 5’ – aga tta aaa atc ctg tgc tcc aac c – 3’ 65.4 24bp 
Forward #5 5’ – tga gat taa aaa tcc tgt gct cca tac – 3’ 65.8 27bp 
Forward #6 5’ – aga tta aaa atc ctg tgc tcc aga c – 3’ 64.3 25bp 
Forward #7 5’ – aga tta aaa atc ctg tgc tcc aca c – 3’ 65.1 25bp 
Reverse 5 – AAA ACT TGG TCA TCA AAA TAT TTA GCC T – 3’ 64.4 28bp 
Probe 5’ – [VIC] agg ttt gcT CCT AAA TCT TAA AAT ATG GAA 
AGC ACC TCA [TAMRA] – 3’ 
74.6 39bp 
Upper case denotes exonic region 
Lower case denotes intronic region 
Underline denotes introduced mismatches 
Bold red denotes discrepancies between RHCE and RHD gene 
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2.3.1 Multiplexing 
Once all RHD exon primer and probe sets were tested for sensitivity (see 
section 2.6.1) and specificity for the corresponding RHD exon, combining 
multiple primer/probe qPCR sets per reaction tube was attempted (i.e. 
‘multiplexing’). Multiplexing samples allows for a higher throughput assay than 
a singlex reaction as a larger number of samples may be tested per reaction 
run. The Rotor-Gene® (Qiagen) instruments in use at the Blood Service have 
5 detection channels, and as such, allow multiplexing of up to 5 qPCR 
reactions in one reaction tube. The project aim is to achieve 4-plex and 5-plex 
qPCR assays combining RHD exon 2/3/4/10 qPCR reactions and RHD exon 
5/6/7/9/CCR5 reactions, respectively, using FAM, VIC, ROX, Cy5 and Quasar 
705 fluorochromes listed in Table 7. These fluorochrome combinations are 
recommended by the manufacturer to avoid ‘cross over’. Cross over is a term 
used to describe emission overlap. Cross over can lead to false positive 
results if fluorochrome emission is detected in more than one Rotor-Gene® 
channel.  
 
Duplicated 4-plex and 5-plex assays will allow for 15 unknown RHD gDNA 
samples to be run in a single 72 tube qPCR assay ring (including 12 tubes for 
controls which are outlined in section 2.5). If this assay were run as a singlex 
qPCR assay, it would only be possible to run a single unknown sample per 72 
well ring. 
 
Samples were initially duplexed to test compatibility and viability of further 
multiplexing. Fluorochrome-probe conjugates utilised for duplex analysis are 
as follows: VIC – exon 2, 6, 10, CCR5; and FAM – exon 3, 4, 5, 7, 9. All 
possible combinations between VIC and FAM probe conjugates were trialled.  
 
Primer/probe sets were then tested in triplex, with RHD exon 2 and exon 9 
being ordered with the Cy5 fluorochrome. Initial pairings were exon 2/3/4; 
2/3/10; 9/7/6; 9/7/CCR5; 9/5/6; 9/5/CCR5. Probes for exon 3 and exon 6 were 
then ordered with the ROX fluorochrome and exon 7 probe ordered with the 
Quasar 705 fluorochrome, with the end aim combination of exons 2/3/4/10 
and 5/CCR5/6/7/9 in mind. The original singlex reactions incorporated a 
TAMRA quencher on the probes, however for the multiplex reactions the 
quencher was replaced with Black Hole Quenchers (BHQ). This is due to the 
TAMRA quencher giving off fluorescence at the same frequency as the ROX 
fluorochrome, which can lead to ‘cross over’ and hence a  false positive result.   
 
Table 7: Exon specific probes and their equivalent fluorochromes. 
Fluorochrome Channel 
Excitation 
Maximum 
(nm) 
Emission Maximum 
(nm) 
Exon specificity of 
conjugated 
oligonucleotide 
FAM Green 470 ± 10 510 ± 5 Exon 4; Exon 5 
VIC Yellow 530 ± 5 555 ± 5 Exon 10; Exon CCR5  
ROX Orange 585 ± 5 610 ± 5 Exon 3; Exon 6 
Cy5 Red 625 ± 10 660 ± 10 Exon 2; Exon 9 
Quasar 705 Crimson 680 ± 5 712 long pass Exon 7 
21 
Chapter 2: Research Design 
Due to reasons outlined in the results section 3.1.2 it was not possible to 
multiplex to a higher level and was decided that triplex was an acceptable 
level of multiplexing for the scope of this project. A triplex reaction allows for 
the testing of 9 samples concurrently in one 72 well ring and so the loss of 
testing throughput was considered acceptable.  
2.4 SNP Genotyping 
Results from Dr Scott’s previous work also revealed an additional 64 non-
hybrid RHD alleles positive for RHD exons 4,5 and 10. These samples were 
sent for further allelic classification via BLOODchip™ at Progenika. A number 
of both DEL associated and RhD negative associated RHD alleles were 
defined and are outlined in Table 8 below. DEL associated alleles were 
determined to make up 2.17% (44/2027) of the RhD negative, RhC and/or 
RhE positive donor panel. 
  
 
Whilst the RHD extended exon scanning gives the ability to determine the 
presence of specific RHD exons, it does not give detailed allelic 
characterisation in the event of positivity for all exons. Further sequencing or 
SNP array characterisation is required. Therefore the second part of this 
project involved designing and validating specific primers and probes for the 
most prevalent DEL alleles (RHD(K409K), RHD(885G>T), RHD(IVS3+1G>A) 
and RHD(94insT)) and RhD negative/RHD positive alleles 
Table 8: RHD allele and predicted RhD phenotype classification of samples positive for 
exons 4, 5 & 10 
RHD allelic description 
 
(N: RHD allele) 
 Predicted 
phenotype 
[Reference] 
N: RhC/c E/e Phenotype 
   
7: RHD(IVS8+1G>A)  RhD negative[8]  
6: RHD(del343)  RhD negative[14]  
4: RHD(IVS3+2T>A)  RhD negative[14] 3: ccEe; 1: Ccee 
1: RHD(487del4)  RhD negative[15]  
1: RHD(361del11nt)  RhD negative[16]  
1: RHD(443C>G) * RhD negative[17]  
1: RHD(IVS2-1G>A) * RhD negative[21]  
1:  RHD(1177T>C)  * Weak D[22] 1: Ccee 
16: RHD(K409K)  DEL[23-25] 1: ccEe; 1: Ccee; 11: Ccee;  
2: CCee; 1: CcEe 
10: RHD(885G>T)  DEL[23, 24] 1: Ccee; 8: Ccee; 1: CCee 
6: RHD(IVS3+1G>A)  DEL[8, 23, 24] 4: Ccee; 1: ccEe; 1: Ccee 
4: RHD(94insT)  DEL[14] 4: Ccee 
2: RHD(IVS1+1G>A)  DEL[26] 2: ccEe 
1: RHD(297del23) * † Unknown 1: ccEe 
1:  RHD(IVS2-2delA) * † Unknown 1: Ccee 
1: RHD(IVS6+2T>A) * † Unknown 1: Ccee 
1: RHD(IVS1+5G>C) * † Unknown 1: Ccee 
* These alleles were defined only after sequencing as SNP profiling gave either a ‘NO 
CALL’ or an ‘Apparently non-neg’ result 
† Neo RHD alleles. 
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(RHD(IVS8+1G>A), RHD(IVS3+2T>A) and RHD(del343C)) present in the 
Australian population. 
 
As the majority of DEL alleles are caused by SNPs or very small insertions, it 
is difficult to design primers and probes to detect the small genetic difference. 
As such it was decided that MGB probes would be most effective for allelic 
discrimination. Due to the presence of a conjugated peptide which binds to the 
minor groove in DNA via Van der Waals forces[111], MGB probes are able to 
form very stable duplexes with ssDNA, allowing shorter probes to be utilised, 
thereby increasing specificity for the target sequence [112-114]. 
 
As a comparative measure a Locked Nucleic Acid (LNA) probe was also 
ordered for the RHD(K409K) allele. LNA probes are a modified dual-labelled 
probe in which the sugar phosphate backbone contains a methylene bridge 
between the 2’-oxygen and the 4’-carbon atoms which locks the structure into 
a bicyclic formation [115]. This changes the conformation of the helix, which 
allows for greater allelic discrimination due to a more stable complex [116]. 
Studies have given mixed results as to whether an MGB modified probe or an 
LNA modified probe is more sensitive and specific [117, 118]. Therefore this 
project trialled both modified probes to determine which is more appropriate 
for use with the RHD gene. 
2.4.1 Design of Primers and Probes 
As with section 2.2, the implementation of the second aim of this project 
requires design of primers and probes. However, instead of aligning the RHD 
and RHCE genes, this section required the alignment of the wildtype RHD 
gene with the DEL associated or RhD negative associated RHD allele. Allelic 
information was gathered from RhesusBase and was BLAST aligned against 
GenBank accession number BN00065.1 (wildtype RHD gene). 
 
As MGB probes are a relatively new technology, and there is currently no 
published information detailing how to calculate the additional degrees Celsius 
that are added to the Tms of probes, it was decided to order MGB probes 
ranging in length (13-18bp) in attempt to achieve specificity to DEL alleles. As 
the two most prevalent DEL alleles in the Australian population are 
RHD(885G>T) and RHD(K409K) (Table 8), these were selected for initial 
testing. Using current manufacturer’s protocol outlined in section 2.2, primers 
and probes were designed around the SNP differences between the DEL 
associated RHD allele and wildtype RHD. RHD(K409K) shows a G>A 
nucleotide change in position 1227 of the RHD gene (exon 9) and 
RHD(885G>T) has a G>T substitution in position 885 (exon 6), compared to 
wildtype RHD.  
 
Based on a previous study which compared sequence specificity and Tms of 
MGB conjugated probes to unmodified probes[114], this study’s probes were 
designed with the SNP change -5/-6 bp from the 3’ end of the probe. Two 
probes were ordered for the RHD(885G>T) allele 16 bp and 13bp in length, 
and 3 probes were ordered for the RHD(K409K) allele 18bp, 15bp and 13bp 
in length. 4 sets of primers and a single 18bp probe was designed and 
ordered for the RhD negative associated allele RHD(del343C), which shows a 
deletion of the cytosine nucleotide at position 343 (within exon 3).The 
RHD(94insT) allele was investigated for MGB probe design, however, 
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considering that the SNP change is a T nucleotide insertion in a run of seven 
Ts at position 94 of the RHD gene, it was assumed to be too difficult to attain 
specificity from overwildtype RHD using qPCR.  
 
After testing of the RHD(885G>T) and RHD(K409K) primer/MGB probe sets, it 
was established that the smallest MGB probe was the most specific. MGB 
probes and primers were then designed using the same protocol for the 
RHD(IVS3+1G>A) DEL associated allele and the RhD negative associated 
alleles RHD(IVS3+2T>A) and RHD(IVS8+1G>A). The RHD(IVS3+1G>A) 
allele has a G>A nucleotide substitution at position 486+1 (within intron 4), the 
RHD(IVS3+2T>A) allele has a T>A substitution at position 486 +2 (within 
intron 4) and the RHD(IVS8+1G>A) has a G>A substitution at position 1153+1 
of the RHD gene (within intron 9).  
 
After initial specificity testing, a second set of primers was ordered for the 
RHD(K409K) and RHD(885G>T) alleles to allow for a more robust assay.  
 
The LNA probe designed for the RHD(K409K) allele was obtained from Sigma 
and included 8 locked nucleic acids.  It was designed by Sigma around the 
MGB probe sequence using the Beacon Designer (Premier Biosoft) program 
to have a Tm of 69°C. All SNP genotyping primer and MGB/LNA probe 
sequences are described in Table 9 
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Table 9: Primers and probes designed for SNP genotyping
Allele Sequence Length  GC % Tm (°C) 
IVS3+1G>A 
Forward 5’ – AAC CTG AGG ATG GTC ATC AG – 3’ 20bp 50 61.6 
Reverse 5’ – agg tcc ctc ctc cca g – 3’ 16bp 68.8 60.2 
Probe 1 5’ – [VIC]TAT CTT CAA Cat gag [MGBBHQ1] – 3’ 15bp 33.4 38.5 
Probe 2 5’ – [VIC]TCT TCA ACa tga g [MGBBHQ1] – 3’ 13bp 38.5 33.0 
IVS3+2T>A 
Forward 5’ – CAA CCT GAG GAT GGT CAT CAG – 3’ 22bp 52.4 64.5 
Reverse 5’ – agg tcc ctc ctc cca gc – 3’  17bp 70.6 64.4 
Probe 1 5’ – [VIC]ATC TTC AAC gag agt [MGBBHQ1]  – 3’  15bp 40 42.9 
Probe 2 5’ – [VIC]CTT CAA Cga gag t [MGBBHQ1]  – 3’  13bp 46.2 35.0 
del343C 
Forward 1 5’ – GTC CTG GCT CTC CCT CTC T – 3’  19bp 63.2 62.6 
Forward 2  5’ – GTC CTG GCT CTC CCT CAC T – 3’ 19bp 63.2 63.5 
Forward 3 5’ – GTC CTG GCT CTC CCT CGC T – 3’ 19bp 68.4 68.5 
Forward 4 5’ – GTC CTG GCT CTC CCT CCC T – 3’ 19bp 68.4 67.0 
Reverse 5’ – TTC CCC AAG ACA GCA TCC A – 3’ 19bp 52.7 66.8 
Probe 5’ – [VIC] ccc cca gTA TTdelG GCT [MGBBHQ1] – 3’ 15bp 56.3 63.4 
del343C v2 
Probe 5’ – [VIC] ccc agT ATT delGGC T [MGBBHQ1] – 3’ 13bp 53.9 37.0
885G>T 
Forward 5’ – CAC CTG ATC CCT TCT CCG – 3’  18bp 61.2 63.3 
Reverse 5’ – GAT CAG CCC AGC CAC AAG – 3’  18bp 61.2 64.6 
Probe 1 5 – [6FAM] TGG CTT GCC ATT GTG C [MGBHQ1] – 3’ 16bp 56.3 63.4 
Probe 2 5’ – [6FAM] CTT GCC ATT GTG C [MGBBHQ1] – 3’  13bp 53.9 37.0 
885G>T v2 
Forward 5’ – GTC ACC TGA TCC CTT CTC CG – 3’   20bp 60 66 
Reverse 5’ – GAT CAG CCC AGC CAC AAG A – 3’ 19bp 58.9 66.6 
K409K 
Forward 5’ – CAT GAG GCT AAA TAT TTT GAT G – 3’  22bp 31 57.7 
Reverse 5’ – aaa tct atc acg tta ata ggt g – 3’ 22bp 31.9 54.1 
Probe 1 5’ – [6FAM] AAG TTT TCT GGA AAg taa [MGBBHQ1] – 3’  18bp 27.8 48.5 
Probe 2 5’ – [6FAM] TTT TCT GGA AAg taa [MGBBHQ1] – 3’ 15bp 26.7 42.1 
Probe 3 5’ – [6FAM] TTC TGG AAA gta a [MGBBHQ1] – 3’ 13bp 30.8 31.0 
LNA Probe 5’ – [6FAM] AAA [+T]C[+T] [+T]A[+C] [+T][+T]T [+C]CA [+G]AA A [BHQ1] – 3’ 19bp 26.3 69  
K409K v2 
Forward 5’ – CCT CAT GAG GCT AAA TAT TTT GAT G – 3’  25bp 36 63.4 
Reverse 5’ – cac tca aaa tct atc acg tta ata ggt g – 3’ 28bp 35.8 63.5 
IVS8+1G>A 
Forward 5’ – CGTGATAGCTCTCACGTCTGG – 3’ 21bp 57.2 64.9 
Reverse 5’ – ggtggaagaaaggtggcc – 3’  19bp 61.2 64.5 
Probe 1 5’ – [VIC]CTCCTGACAGatcag[MGBBHQ1]  - 3’ 15bp 53.4 44.7 
Probe 2 5’ – [VIC]CCTGACAGatcag[MGBBHQ1] – 3’ 13bp 53.9 37 
Upper case denotes exonic region; Lower case denotes intronic region; Bold red denotes SNP difference between 
RHD and RHCE; Underlined denotes introduced mismatches for higher specificity ; Bold blue denotes SNP difference 
between Wildtype and DEL allele; [+X] denotes LNA
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2.5 qPCR Reaction Parameters and Cycling Conditions 
 
The qPCR assays were performed on a Rotor-Gene®  6000 or  Rotor-Gene®  
Q and utilised the following reaction mix volumes (Table 10), extrapolated for 
use with the QIAgility™ (Qiagen) for automated pipetting into 72 well Rotor-
Gene® rings.  
 
Each multiplex reaction contained either 2 or 3 separate primer and probe 
sets, as explained in section 2.2.1. Table 10 gives the volumes and 
concentrations of singlex, duplex and triplex reactions with each relative 
primer/probe set designated a letter (A, B and C). For example, in a triplex 
reaction detecting exons 3, 4 and 10; exon 3 is primer/probe set A, exon 4 is 
primer/probe set B and exon 10 is primer/probe set C. 2 x TaqMan® (Roche) 
Mastermix (MM) was used for all reactions and all primer and probe stock 
solutions were 5µM concentrations. 
 
 Table 10: qPCR reaction mix volumes and concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 5µL volume of gDNA was added to each ring well during the QIAgility 
process to make a total of 25µl liquid per reaction well. gDNA that was 
previously collected for Dr Scott’s population screening was diluted to a 
1ng/µL concentration. All gDNA samples were vortexed and centrifuged for 3 
minutes at 12,000rpm before use.  
 
For RHD exon mapping, gDNA from blood samples with R1R2 phenotype 
were used as a positive control. The CCR5 gene was used as an internal 
positive control.  Negative controls comprised gDNA extracted from RhD 
negative blood samples with the rr, r’r and r”r phenotype. An NTC was also 
included for internal negative control.  
 Volume (µL)  
 Singlex Duplex Triplex
Final 
Concentration 
(nM) 
2 x TaqMan® Mastermix 12.5 12.5 12.5  
Primer A 
 
1.5 1.5 1.5 300 
Primer B 
 
N/A 1.5 1.5 300 
Primer C 
 
N/A N/A 1.5 300 
Probe A 
 
0.25 0.25 0.25 50 
Probe B 
 
N/A 0.25 0.25 50 
Probe C N/A N/A 0.25 50 
dH2O 
5.75 4.00 2.25  
gDNA 5.00 5.00 5.00  
Total 25  
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Autogain optimisation for the Rotor-Gene® was set on the known positive 
controls - R1R2 samples for the RHD exon mapping and the DEL positive or 
RHD positive/RhD negative samples for the SNP genotyping – all of which 
were previously confirmed by BLOODchip™. For analysis of results, threshold 
was set on the exponential region of the amplification curve.  
 
For the SNP genotyping assays, samples that were confirmed via 
BLOODchip™ to possess the appropriate DEL or RhD negative allele were 
included as a positive control. Confirmed wildtype R1R2 samples were used 
as a negative control and an NTC lane was included as an internal negative 
control. All samples were run in duplicate. 
 
Cycling conditions for the RHD exon mapping were as follows: 50ºC for 2 
minutes (UNG incubation); 95ºC for 10 minutes; 45 cycles of 95ºC for 15s and 
59 ºC for 60s. Conditions remained the same for the SNP genotyping, with the 
exception of the extension/annealing stage, which was varied across a 
temperature range of 50ºC - 64ºC.  
 
When problems with aberrant amplification of the RHCE gene arose during 
testing or higher temperatures were needed to be tested, JumpstarTaq 
mastermix (Roche) was utilised in place of the basic TaqMan mastermix. The 
cycling conditions are as follows: 94ºC for 2 minutes; 45 cycles of 94ºC for 30 
seconds, 59ºC for 30 seconds, 72ºC for 2 minutes; final extension at 72ºC for 
5 mins.  
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2.6 Validation of qPCR Assays 
2.6.1 Sensitivity Assay 
Once all primer/probe sets were determined to be specific for the 
corresponding RHD exon at 59°C a sensitivity assay was undertaken. As per 
qPCR technical manuals, a sensitivity assay is a useful tool to determine the 
dynamic range, robustness and therefore reproducibility of a multiplex qPCR 
assay. A qPCR assay is performed on the gDNA sample across a range of log 
dilutions. Figure 8 shows an example taken from the Eurogentec qPCR guide, 
which is across a 7-log dilution range. The Cts are then plotted for results 
analysis.   
 
Kutayvin et al [114] suggests a 7-log base change in gDNA concentration, 
however the concentration of EZ1 DNA Blood 350µl kit extracted gDNA does 
not vary across a 7-log base scale. Currently, the NIPA study uses a standard 
curve incorporating a 4-log base change from 0.02ng/µL to 20ng/µL, however 
this test involves amplifying free foetal DNA in maternal plasma and as such 
will be considerably lower. At an early gestational age, some samples have 
been found to be as low as 0.03ng/µL. Based on these methodological 
assumptions, a 6-log base range from 0.001ng/µL to 100ng/µL was tested.  
 
Data analysis, with special focus on the correlation coefficient (R2 value > 0.98 
preferred), standard deviation and slope will determine whether the qPCR 
primer/probe reactions are robust and the reaction is efficient across a certain 
dilution range.  This is important to validate the procedure for use in a high 
throughput system that does not first require quantification of gDNA 
concentration prior to qPCR analysis.  
 
Sensitivity assays were performed on all singlex assays, followed by duplex 
and finally all triplex assays, which were compared to concurrently run singlex 
assays.  
 
 
 
 
 
Figure 9: Example of a 7-log dilution sensitivity assay (A) and subsequent standard curve (B), comparing 
singlex and duplex reactions. 
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2.6.2 Verification of Results against Blinded Samples 
 
To validate the specificity of the extended RHD exon mapping qPCR assays, 
including both a mix of DEL, RHD-CE hybrid alleles, RHD negative alleles and 
RHD positive alleles were tested (49 samples in total). Testing of the samples 
was blinded. A BLOODchip™ confirmed R1R2 sample was included as an 
RHD positive control, rr, r’r and r”r samples were included as RHD negative 
controls and an NTC lane was included as an internal negative control. The 
CCR5 primer/probe set allowed for an added internal positive control. Cycling 
conditions outlined in section 2.4 were used. 
 
As with the extended RHD mapping assay, the SNP genotyping assays were 
also tested against panels of blinded samples. The first set of alleles tested 
were the RHD(K409K) and the RHD(885G>T) alleles. These were tested 
using two Rotor-Gene® rings per allele and 49 unknown samples that 
included both a number of wildtype RHD alleles and the two DEL alleles in 
unknown frequencies.  These were tested with the aforementioned cycling 
conditions, but with an annealing temperature of 61ºC.  Positive controls were 
BLOODchip™ confirmed RHD(K409K) or RHD(885G>T samples at a 
concentration of 1ng/µL of gDNA. A BLOODchip™ confirmed R1R2 sample 
was included as a negative control and an NTC lane was included as an 
internal negative control. Results were determined to be positive or negative 
for the DEL alleles. The same blinded assay was performed for the 
RHD(IVS8+1G>A) at an annealing temperature of 63ºC against a panel of 27 
blinded samples, due to the lowered frequency of occurrence and hence 
availability of this allele.  
2.7 Epitope Mapping 
 
There remain a number of undescribed anti-D reactivity patterns for DEL 
alleles detected within the Australian blood donor panel; hence this project 
performed extended serological testing of red cells derived from undescribed 
DEL alleles using the adsorption-elution/indirect antiglobulin test (IAT) and 9 
D-SCREEN (Diagast™) monoclonal anti-D antibodies. Currently, requested 
adsorption-elution/IAT testing at the Blood Service involves the use of the 
MCAD6 anti-D MoAb only, however current research has shown that the 
MCAD6 MoAb does not react against all DEL associated RHD alleles [119]. 
Further analysis of DEL alleles with undescribed anti-D reactivity patterns 
using the 9 D-SCREEN™ MoAbs will assess the potential antigenicity of the 
undescribed DEL types and allow for the development of more sensitive 
serological blood phenotyping at the Blood Service, specific to the Australian 
population.  
 
The reactivity patterns of these variants will be defined using the 
aforementioned manual adsorption-elution/indirect antiglobulin test. Packed 
RBCs (pRBCs) from donors previously identified as DEL or RHD positive/RhD 
negative donors will be washed in a phosphate buffered saline solution (PBS) 
(PBS: 7.8 mM Na2HPO4, 2.2 mM KH2PO4, 138.6 mM NaCl, pH 7.3). These 
RBCs will then be mixed at a ratio of 1:2 with each of the 9 D-SCREEN™ 
MoAbs separately and incubated at 37°C for one hour. Following incubation, 
the mixture is spun (3000rpm, 2 minutes), supernatant discarded and pRBCs 
are hand washed six times with PBS. To elute anti-D, one part washed 
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pRBCs will be mixed vigorously with one part EDTA/Glycine-HCl (49.5 mM 
K2EDTA,  [79.9 mM Glycine, 0.72% NaCl, pH 1.8]) for 2 minutes. One drop of 
1M Tris/0.9% NaCl is then added to the mixture before it is spun as described 
to remove cell debris. The eluate is collected and adjusted to pH 7.5-8.5 using 
1M Tris/0.9% NaCl before one drop of 30% BSA solution (CSL) is added to 
stabilise any eluted anti-D. Secondly, for the indirect antiglobulin test, wash 
and eluate solutions will be incubated with equivolumes of papainised panel 
RBCs suspended in Celpresol™ LISS (CSL) for 20 minutes at 37ºC. After 
incubation, RBCs will be washed and then incubated with anti-human IgG 
(CSL) at room temperature. Agglutination is assessed microscopically. For the 
test to be valid, the last wash fraction must show no agglutination. 
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Chapter 3: Results 
3.1 Extended RHD Exon Mapping 
3.1.1 Singlex qPCR Assay Results 
 
In order to detect the RHD gene via qPCR, it was important that false positive 
results were not obtained via RHCE gene amplification. Following 
optimisation, all exon primer/probe sets were found to be specific for the RHD 
gene and no false positive results were obtained from RHCE gene 
amplification. The RHD positive (R1R2) controls showed a positive 
amplification result for all exons and the RHD negative (rr, r’r, r”r) and internal 
negative (NTC) controls showed no amplification. The internal positive control 
(CCR5 gene) showed positive amplification of all gDNA samples. Table 11 
shows a summary of the optimised singlex results.  
 
Table 11: Singlex qPCR assay amplification results 
 
   Internal 
Positive 
Control 
Amplification Result 
(Ct) 
  Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 9 Exon 10 CCR5 
Internal 
Negative  
Control 
NTC Negative Negative Negative Negative Negative Negative Negative Negative Negative 
Negative 
Control rr Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.99) 
Negative 
Control 
r’r 
 Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.89) 
Negative 
Control 
r”r 
 Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.84) 
Positive 
Control R1R2 
Positive 
(27.90) 
Positive 
(26.85) 
Positive 
(29.32) 
Positive 
(26.54) 
Positive 
(28.29) 
Positive 
(28.46) 
Positive 
(31.00) 
Positive 
(27.97) 
Positive 
(29.27) 
 
During the optimisation process, three primer/probe sets initially were not 
specific and required redesign and optimisation. The first round of results 
showed aberrant amplification of exon 2 in the r’r lane only. This was 
assumed to be due to the RHc/RHC SNP located at position 150. The primers 
and probes were not amplifying the RHCE gene where the RhCE phenotype 
was present but did amplify the RHCE gene when the RhcE phenotype was 
present. Primers and probes were redesigned to exclude this section of the 
gene and as such, intronic regions were investigated.  
 
Exon 6 showed late Ct amplification in every lane, including the NTC lane. To 
combat this non-specific amplification, JumpstarTaq was used in place of the 
basic TaqMan mastermix. The primers and probe were also redesigned to 
avoid self-complementarity between the primers and probe.  
 
Exon 9 showed no amplification in any lanes, including the positive R1R2 
control. They were then tested at lower temperatures to determine if the Tm 
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was too low and amplification was achieved but was not specific, with 
amplification in the rr, r’r and r”r negative control lanes. These primers and 
probe were then redesigned.  
 
After redesign, exon 2 primers and probes were specific for the RHD gene but 
showed later Ct than the other sets. Exon 6 was specific for the RHD gene; 
however exon 9 again showed no amplification of any lanes.  
 
As there was no amplification at all at the standard 59°C, original primers and 
probe for exon 9 were tested at 1°C intervals from 50°C-55°C. R1R2, rr, r’r, 
and r”r samples all showed consistent amplification at all temperatures with 
Cts of 29-30 for the negative controls and 27-30 for the positive controls. 
Figure 9 shows the amplification 
curve at 50°C, with the pink trace 
indicating the R1R2 positive control.  
 
The second set of primers and probe 
again showed no amplification of 
either positive or negative controls at 
59°C. When tested across a 
temperature range of 50°C-58°C all 
samples showed amplification, as 
seen for the first set of 
primers/probe. 
 
The third set of primers/probe 
included 7 different forward 
primers, a new reverse primer and 
a new probe (as described in Table 
6, section 2.2). Primer set #1 and 
#2 (red and yellow traces 
respectively) showed amplification 
of negative controls. All remaining 
primer sets showed amplification of 
positive controls and no 
amplification of negative controls. 
The lowest Ct of acceptable primer 
sets was #5 (solid teal trace in 
Figure 10), however #7 had a more 
efficient amplification curve and was selected for further use (solid orange 
trace shown in Figure 10). Note that the pink trace in Figure 10 was an RHD 
exon 5 positive control for comparison of amplification curves. 
 
  
  
Figure 10: Amplification curve of the 
original set of exon 9 primer/probe at 50°C, 
showing non specific amplification of 
negative controls.  
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Figure 11: 7 different primer sets were trialled 
for exon 9. Sets 1 and 2 show amplification of 
negative controls. Positive controls are shown 
as solid lines, negative controls as dashed, 
dotted and thin lines.  
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(A)          (B) 
 
 
Figure 13: Amplification curve of the (A) Cy5 labelled exon 2 probe in a singlex (red), in a 2/3/10 triplex 
(pink) and 2/4/10 triplex (green) and (B) Cy5 labelled exon 9 probe in a singlex (red), in a 9/5/6 triplex (pink) 
and 9/7/6 triplex (green) 
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Figure 12: Amplification curve of exon 4 and 5 in a singlex reaction and duplex reactions 
with exon 2. Singlex exon 4 – yellow; singlex exon 5 – green. Duplexed with exon 2: exon 
4 – purple; exon 5 – orange. 
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3.1.2 Multiplexed qPCR Assay Results 
 
RHD primer and probe sets were initially duplexed; probes with fluorochromes 
VIC and FAM were paired in each assay. Each duplexed exon combination 
was successfully specific with no non-specific binding of the RHCE gene. An 
example is shown in Figure 11, which shows the amplification curve of exons 
4 and 5 in a singlex (exon 4 – yellow trace, exon 5 – green trace) and in an 
exon 2/4 duplex - purple and an exon 2/5 duplex - orange.) The exon 2 and 3 
duplex did however show an uneven reaction, with the exon 3 primers and 
probes being favoured in the assay.  
Following the ordering of new probe fluorochromes, triplexes were trialled with 
the following combinations: exon 2/3/10 or exon 2/4/10, exon 9/7/6 or exon 
9/5/6. Initially, amplification of the exons 3, 4 and 10 were all comparable to 
the singlex reactions, however exon 2 showed very little amplification in the 
red emission channel in either of triplexes 2/3/10 or 2/4/10. Figure 12A shows 
this decrease in amplification of Cy5 labelled exon 2 probe by comparing a 
singlex reaction (red trace) with two triplex reactions (pink trace – exons 
2/3/10, green trace – exons 2/4/10)   Probe concentration of exon 2 was 
increased to 100nM and 200nM, however this did not promote greater 
amplification.  
33 
Chapter 3: Results 
 
In the triplexes that included exon 9, a decrease in amplification integrity was 
also observed, but not to the same extent as the exon 2 triplexes. Figure 12B 
shows the decrease in integrity of amplification curves of the triplex reactions 
(exon 9/5/6 triplex – pink trace and exon 9/7/6 triplex – green trace) in 
comparison to a singlex reaction (red trace). As the loss of amplification 
integrity occurred only when using the Cy5 flurochrome labelled probes, a 
comparative qPCR assay was run. Figure 13 shows the decrease in reaction 
quality of Cy5 fluorochrome that is affecting the assay. Whilst the Cts of the 
sample did not change, there was a decrease in size of the amplification curve 
above threshold.  
 
To determine whether exon 9 amplification would occur in a quadruplex, 
exons 9, 6, 5 and CCR5 were assayed together. Unfortunately, amplification 
of exon 9 in the quadruplex did not occur. As such it was decided to design 
the qPCR assay with three triplex combinations; exons 2/7/9 (with the original 
VIC and FAM fluorochromes conjugated to the exon 2 and exon 9 probes 
respectively) and exons 3/4/10 and 5/6/CCR5.  
 
Triplexed assays including the ROX conjugated probes gave comparable 
results to the duplexes with VIC and FAM labelled probes. For the exon 3/4/10 
triplex, it appears that no one primer set particularly favoured the reaction as 
all three amplification curves were similar in the triplex as the singlex.  This 
can be seen in Figure 14, which gives a comparison of the curves in singlex 
and triplex for the three different Rotor-Gene® channels. 
 
 
 
 
(A)                     (B)     
    
        (C) 
 
 
Figure 14: Comparison of amplification curves of (A) Cy5 labelled exon 2 (red) and exon 9 probe (green) to 
the (B) original VIC labelled exon 2 probe (blue) and (C) FAM labelled exon 9 probe (yellow) 
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The second triplex, exons 5/6/CCR5 includes the internal positive control. As 
such, the lanes containing the negative controls of rr, r’r and r”r gDNA were 
positive as well as the positive R1R2 control. Exon 5 and CCR5 primers 
favoured the reaction slightly more than the exon 6 primers, however as seen 
in Figure 15, this is not a significant difference.  
 
       (A)       (B)         
 
(C) 
 
Figure 15: Comparison of amplification curves in a singlex and in a exon 3/4/10 triplex. (A) Exon 3 – red 
denotes singlex, pink denotes triplex (B) exon 4 - blue denotes singlex, pink denotes triplex (C) exon 10 – 
orange denotes singlex, pink denotes triplex. 
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Figure 16: Comparison of amplification curves in a singlex and in a exon 5/6/CCR5 triplex. (A) Exon 5 – 
red denotes singlex, pink denotes triplex (B) exon 6 - blue denotes singlex, pink denotes triplex (C) exon 
CCR5 – orange denotes singlex, pink denotes triplex. rr, r’r, r”r samples are also positive in (C) and are 
shown respectively by thin, dotted and dashed lines. 
Cycle
5 10 15 20 25 30 35 40 45
N
or
m
. F
lu
or
o.
-0.410
-0.610
-0.810
-1.010
-1.210
-1.410
-1.610
-1.810
-2.010
-2.210
-2.410
-2.610
-2.810
Threshold
Cycle
5 10 15 20 25 30 35 40 45
N
or
m
. F
lu
or
o.
-1.010
-1.210
-1.410
-1.610
-1.810
-2.010
-2.210
-2.410
-2.610
-2.810
Threshold
Cycle
5 10 15 20 25 30 35 40 45
N
or
m
. F
lu
or
o.
-0.410
-0.6
10
-0.8
10
-1.0
10
-1.210
-1.4
10
-1.6
10
-1.8
10
-2.0
10
-2.2
10
-2.4
10
-2.610
-2.8
10
Threshold
35 
Chapter 3: Results 
As expected for the exon 2/7/9 triplex, exon 2 and exon 9 gave produced 
weaker amplification curves in the triplex, which can be seen in Figure 16 A 
and C, whereas exon 7 remained constant with its singlex counterpart, as 
shown in Figure 16 B. 
 
To optimise the exon 2/7/9 triplex to favour exon 9 more in the reaction, an 
assay was run with modified exon 9 mastermixes. The first contained an exon 
2/7/9 triplex with the original equal concentrations of exon 2, 7 and 9 primers, 
the second contained the same triplex with increased exon 9 primer 
concentration of 500nM, the third contained increased exon 9 probe 
concentration of 200nM. These were all compared to the singlex reactions. 
Figure 17 shows that the increased probe concentration actually decreased 
the amplification of exons 2 and 9 in the triplex, whereas the increase in 
primer concentration increased the amplification integrity. Exon 7 is unaffected 
by the increase in either primer or probe of exon 9.  
  
(A)              (B)          
 
(C) 
 
 
Figure 17: Comparison of amplification curves in a singlex and in a exon 2/7/9 triplex of (A) exon 2 – red 
denotes singlex, pink denotes triplex (B) exon 7 - blue denotes singlex, pink denotes triplex (C) exon 9 – 
orange denotes singlex, pink denotes triplex. 
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Figure 18: Optimisation of exon 9 amplification in an exon 2/7/9 triplex. (A) Exon 2 in a singlex – red, in the 
original triplex – pink, in the 500nM exon 9 primers triplex – green, in the 200nM exon 9 probe triplex – yellow. 
(B) Exon 7 in a singlex – blue, in the original triplex – pink, in the 500nM exon 9 primers triplex – green, in the 
200nM exon 9 probe triplex – yellow. (C) Exon 9 in a singlex – orange, in the original triplex – pink, in the 500nM 
exon 9 primers triplex – green, in the 200nM exon 9 probe triplex – yellow. 
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Figure 19:Graphic representation of Ct results obtained from the RHD(885G>T) SNP genotyping  
qPCR assay across a 50-62°C range of annealing temperature  
3.2 SNP Genotyping 
Three RHD variants were detected conclusively and without amplification of 
the wildtype RHD gene (R1R2) using MGB probes. These included the two 
most prevalent DEL alleles in the Australian population: the RHD(K409K) and 
RHD(885G>T) DEL alleles; and the most common RhD negative associated 
allele:, RHD(IVS8+1G>A). The primer/MGB probes sets designed for the third 
most common DEL allele in the Australian population, RHD(IVS3+1G>A), and 
two common RhD negative variants, RHD(del343C) and RHD(IVS3+2T>A), 
did not achieve specificity for the corresponding RHD variant.  
3.2.1 RHD(885G>T) Allele  
 
2 MGB probes were trialled for specificity for the RHD(885G>T) DEL allele 
across a 12°C annealing temperature difference. The 16bp probe (probe 1) 
did not show specificity for the DEL allele; however the 13bp probe (probe 2) 
showed specificity at 60°C, 61°C and 62°C, as shown in Figure 18.  
Figure 19 shows a comparison of amplification curves at a non-specific 
temperature (50°C) and again at the first point of specificity for probe 2 
(60°C). At 50°C, neither probe 1 or probe 2 are specific for RHD(885G>T) 
over wildtype RHD, as indicated by the wildtype R1R2 traces (probe 1: solid 
pink trace; probe 2: dashed pink trace) above threshold (horizontal line). From 
Figure 19B it is clear that the specificity for the DEL allele increases with an 
increase in temperature; however the amplification curve for the shorter probe 
loses integrity towards higher temperatures.    
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Whilst this is a robust temperature range, higher specificity was desired and 
primers were redesigned with a higher Tm. After redesign of primers, 
specificity for the DEL allele was achieved for both the 16bp (probe 1) and 
13bp (probe 2) probes. The shorter probe was specific from 57-64°C and the 
longer probe from 61-64°C, as shown in Figure 20. 
 
 
(A)        
 
(B) 
 
 Figure 20: (A) RHD(885G>T) amplification curve at 50°C (B) RHD(885G>T) 
amplification curve at 60°C. Purple denotes RHD(885G>T) allele, pink 
denotes R1R2 wildtype allele. Solid lines denote probe 1, dotted denote 
probe 2.  
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Figure 21: Graphic representation of Ct results obtained from the RHD(885G>T) SNP genotyping qPCR  
assay with redesigned primers across a 57-64°C range of annealing temperature  
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Figure 22: (A) RHD(885G>T) amplification curve of redesigned primers at 57°C and (B) 
RHD(885G>T) amplification curve at 61°C. Purple denotes RHD(885G>T) allele, pink 
denotes R1R2 wildtype allele. Solid lines denote probe 1, dotted lines denote probe 2. 
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Figure 21 shows a comparison of amplification curves (for the assays with 
redesigned primers) at a temperature in which probe 1 does not show 
specificity (57°C) and again at the first point of specificity (61°C).  Figure 21A 
shows that only probe 2 is specific for RHD(885G>T) over wildtype RHD, as 
indicated by the probe 2 wildtype R1R2 trace (probe 1: solid pink trace; probe 
2: dashed pink trace) above threshold. At 61°C in Figure 21B both probes 
achieved specificity for the RHD(885G>T) as seen by both wildtype R1R2 
probe traces beneath threshold.  
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Figure 23: Graphic representation of Ct results obtained from the RHD(K409K) SNP genotyping 
qPCR assay across a 50-62°C range of annealing temperature 
3.2.2 RHD(K409K) Allele 
 
3 MGB probes were trialled for specificity for the RHD(K409K) DEL allele 
across a 12 degree annealing temperature range; 18bp – probe 1, 15bp – 
probe 2, 13bp – probe 3. Unfortunately aberrant results were obtained at 57°C 
due to a fault in the Rotor-Gene® equipment. Regardless, specificity was only 
obtained for the RHD(K409K) allele at 59°C, after which point annealing 
temperature was too high for amplification, as shown in Figure 22.   
 
 
  
41 
Chapter 3: Results 
Figure 23A shows the lack of specificity for the RHD(K409K) allele over the 
wildtype RHD as indicated by the wildtype R1R2 traces (probe 1: solid red 
trace; probe 2: dashed red trace; probe 3: thin red trace) above threshold. 
Specificity for the DEL allele for all three probes is achieved at 59°C as shown 
in Figure 23B by all wildtype R1R2 traces under threshold. Figure 23B also 
shows that the amplification curve declines rapidly toward higher 
temperatures and as such primers were redesigned. 
 
  
  
       (A)        
 
      (B) 
 
Figure 24: (A) RHD(K409K) amplification curve at 50°C (B) RHD(K409K) 
amplification curve at 59°C. Blue denotes RHD(K409K)  allele, red denotes R1R2 
wildtype allele. Solid lines denote probe 1, dotted line denotes probe 2, dashed line 
denotes probe 3. 
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Figure 25: Graphic representation of Ct results obtained from the RHD(K409K) SNP genotyping 
 qPCR assay with redesigned primers across a 57-64°C range of annealing temperature 
 
After redesign of primers, specificity for the RHD(K409K) allele was achieved 
for all 3 probes. The 18bp probe (probe 1) was specific from 62-64°C and 
both the 15bp (probe 2) and 13bp (probe 3) probes were specific from 61-
64°C, as shown in Figure 24. 
Figure 25 shows the increase in specificity at a higher temperature with little 
degradation of the amplification curve of the RHD(K409K) positive sample. In 
contrast to the original primers, very little integrity is lost with temperature 
increase. Figure 25A shows that all 3 probes are over threshold for the 
wildtype R1R2 samples (probe 1: solid red trace; probe 2: dashed red trace; 
probe 3: thin red trace) at 57°C. Specificity for the DEL allele (probe 1: solid 
blue trace; probe 2: dashed blue trace; probe 3: thin blue trace) is achieved at 
61°C as shown in Figure 25B.  
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     (A) 
 
     (B) 
 
Figure 26: (A) RHD(K409K)  amplification curve at 57°C (B) RHD(K409K) amplification 
curve at 61°C. Blue denotes RHD(K409K)  allele, red denotes R1R2 wildtype allele. Solid 
lines denote probe 1, dotted line denotes probe 2, dashed line denotes probe 3. 
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An LNA probe was also trialled for use with the RHD(K409K) allele. It was 
trialled with both the original primers and the redesigned primers. Specificity 
for the DEL allele (dark blue trace) over the wildtype R1R2 allele (red trace) 
was not achieved until the assay was run at 66°C, at which point the integrity 
of the amplification curve was minimal, as shown in Figure 26.  
(A)         (B) 
 
Figure 27: Comparison of RHD(K409K)  LNA assay at 59°C (A) and 66°C (B) showing the increase in 
specificity but loss of amplification integrity. Blue denotes RHD(K409K)  allele, red denotes R1R2 wildtype. 
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(A)             (B) 
 
Figure 29: (A) RHD(IVS8+1G>A) amplification curve at 59°C and (B) RHD(IVS8+1G>A) amplification curve 
at 63°C. Green denotes RHD(IVS8+1G>A) allele probe 1, orange denotes RHD(IVS8+1G>A) allele probe 2, 
red denotes R1R2 wildtype allele probe 1 and blue denotes R1R2 wildtype allele probe 2. 
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Figure 28: Graphic representation of Ct results obtained from the RHD(IVS8+1G>A)SNP genotyping qPCR assay 
with redesigned primers across a 59-66°C range of annealing temperature. 
 
 
3.2.3 RHD(IVS8+1G>A) Allele 
 
Two separate MGB probes were also ordered for the RhD negative allele 
RHD(IVS8+1G>A), one at 15bp (probe 1) and one at 13bp (probe 2). The 
RHD(IVS8+1G>A) primer/probe set achieved specificity at 63°C, a higher 
temperature than the other successful sets by 2°. It was however specific 
across a temperature range of 63°C-66°C, as shown in Figure 27. Higher 
temperatures were not investigated due to the upper temperature limits of the 
Taqman mastermix. 
Figure 28 below shows a comparison of the amplification curve of the 
RHD(IVS8+1G>A) assay at 59°C and at 63°C, the first point of specificity. 
Whilst the amplification curve does lose integrity, it is still a clear distinction 
between a positive and a negative result. 
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3.2.4 RHD(del343C) Allele 
 
Detection of the RhD negative associated RHD(del343C) SNP proved 
unsuccessful. One MGB probe was ordered at 15bp and the four forward 
primers already in use for RHD exon 3 detection were used. Unfortunately 
RHD(del343C) specificity was not obtained and in fact the primer/probe set 
had slightly more affinity toward the RHD wildtype allele, possibly due to the 
high Tm of the probe. Figure 29 shows the lack of specificity across a 50°C-
62°C temperature range. Figure 30 shows an example of the amplification 
curve of the RHD(del343C) SNP genotyping assay at 59°C. 
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Figure 31: RHD(del343C) amplification curve at 59°C. R1R2 wildtype allele is shown in 
orange and RHD(del343C) allele is shown in teal. Solid line denotes primer set 1, dotted 
denotes primer set 2, dashed denotes primer set 3 and hairline denotes primer set 4.  
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Figure 30: Graphic representation of Ct results obtained from the RHD(del343C) 
SNP genotyping qPCR assay across a 50-62°C range of annealing temperature. 
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(A)          (B) 
  
 Figure 32: (A) RHD(IVS3+2T>A) amplification curve at 55°C and (B) RHD(IVS3+2T>A) amplification curve at 
60°C. Blue denotes RHD(IVS3+2T>A) allele, red denotes R1R2 wildtype allele, yellow denotes NTC. Thin line 
denotes probe 1 primer 1, dotted denotes probe 2 primer 1, dashed denotes probe 2 primer 1 and a thick line 
denotes probe 2 primer 2. 
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Figure 33: RHD(IVS3+2T>A) amplification curve at 55°C with RHD 
exon 10 R1R2 amplification in brown. Blue denotes 
RHD(IVS3+2T>A) allele, red denotes R1R2 wildtype allele, yellow 
denotes NTC. Thin line denotes probe 1 primer 1, dotted denotes 
probe 2 primer 1, dashed denotes probe 2 primer 1 and a thick line 
denotes probe 2 primer 2. 
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3.2.5 RHD(IVS3+2T>A) Allele 
 
As with the RHD(885G>T) allele, 2 separate probes were ordered for the 
RHD(IVS3+2T>A) allele at 15bp and 13bp. As the RHD(IVS3+2T>A) and 
RHD(IVS3+1G>A) are very similar genetically, forward and reverse primers 
were able to be interchanged. As such, two sets of primers were ordered with 
slightly different Tms. Fig 31 below shows a comparison of the amplification 
curve of the RHD(IVS3+2T>A) assay at 55°C and at 60°C. This assay was 
unsuccessful as there appears to be very little amplification of either the 
RHD(IVS3+2T>A) allele or the wildtype allele occurring.  
 
Figure 32 shows the same assay at 59°C with the addition of RHD exon 10 
amplification (shown in brown) of an R1R2 sample as a comparison to show 
the lack of amplification of the RHD(IVS3+2T>A) allele.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
Chapter 3: Results 
(A)            (B)     
  
Figure 34: RHD(IVS3+1G>A) amplification curve at 55°C and (B) RHD(IVS3+1G>A) amplification curve at 60°C. 
Purple denotes RHD(IVS3+1G>A) allele, green denotes R1R2 wildtype allele, blue denotes NTC. Thin line 
denotes probe 1 primer 1, dotted denotes probe 2 primer 1, dashed denotes probe 2 primer 1 and a thick line 
denotes probe 2 primer 2. 
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 3.2.6 RHD(IVS3+1G>A) Allele 
 
The RHD(IVS3+1G>A) assay was designed and run with the same 
parameters as the RHD(IVS3+2T>A) assay with 15bp and 13bp probes and 
two sets of primers. Whilst specificity for the DEL allele was achieved, the 
same lack of amplification occurred as with the RHD(IVS3+2T>A) assay, as 
can be seen in Figure 33.  
 
Figure 34 shows the same assay at 55°C with concurrent amplification of 
RHD exon 10 shown in brown, to show lack of RHD(IVS3+1G>A) 
amplification. 
 
  
Figure 35: RHD(IVS3+1G>A) amplification curve at 55°C with RHD exon 10 
R1R2 amplification in brown. Purple denotes RHD(IVS3+1G>A) allele, 
green denotes R1R2 wildtype allele, blue denotes NTC. Thin line denotes 
probe 1 primer 1, dotted denotes probe 2 primer 1, dashed denotes probe 2 
primer 1 and a thick line denotes probe 2 primer 2. 
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3.3 Validation 
3.3.1 Sensitivity Assay 
 
Once all primers were optimised to be specific for the RHD gene, sensitivity 
was determined using the aforementioned sensitivity assay across a 4-log 
base change in gDNA concentration. Initially a 6-log base sensitivity assay 
was implemented, however the only primer/probe sets to be sensitive across 
this range were exons 3,4,5 and 7. Correlation coefficient was required to be 
0.98 or greater to be considered sensitive across a 6 log base. Efficiency of 
the reaction is measured by the slope, with an acceptable range of 90-110% 
being between 3.1 - 3.6. For the remaining primer/probe sets, exon 9, 10 and 
CCR5 achieved acceptable sensitivity after discounting the 100ng gDNA 
sample from the study. Figure 35 shows that exon 6 and exon 2 were less 
sensitive in the lowest range (0.001ng gDNA), however were acceptable 
across a 4-log base range of 0.01ng – 10ng.  
 
 
When testing robustness of the DEL primer and probe sets, a number of 
combinations were trialled. For the RHD(885G>T) assay, both probes were 
tested using the original primers and the redesigned primers. As expected, 
specificity for the RHD gene was lost when the longer probe was used, with 
both the original and redesigned primers (see Figure 36). Probe 2 however 
retained specificity and sensitivity across a 4 log base concentration change 
(see Figure 37). The efficiency of the reaction when using the original primers 
was decreased, however the assay involving the new primers was within the 
acceptable range. 
 
 
 
 
 
 
 
RHD Exon Sensitivity Assay
Concentration (ng)
C
t
0.0001 0.001 0.01 0.1 1 10 100 1000
15
20
25
30
35
40
45
Exon 2
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 9
Exon 10
Exon CCR5
 
Figure 36: Sensitivity assay standard curve across a 6 log base change in 
concentration of gDNA for all RHD exons.
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For the RHD(K409K) allele, the three probes were tested for sensitivity using 
the redesigned primers only, as the original primers showed no amplification 
at 61°C. Figure 38 shows that the correlation coefficient of probe 2 is not 
sufficiently high enough, however results for both probe 1 and 3 are 
acceptable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The longer probe for the RHD(IVS8+1G>A) allele was found to have both an 
acceptable correlation coefficient and was within the accepted range for assay 
efficiency, as shown in Figure 39. The shorter probe however did not have 
either acceptable efficiency or sensitivity. 
 
  
Figure 39: Sensitivity assay standard curve across a 4 
log base change in concentration for the RHD(K409K) 
allele. 
 
Figure 40:  Sensitivity assay standard curve across 
a 4 log base change in concentration for the 
RHD(IVS8+1G>A) allele. 
 
Figure 37: Sensitivity assay standard curve across a 4 
log base change of concentration for the RHD(885G>T) 
allele, probe 1. 
Figure 38: Sensitivity assay standard curve across 
a 4 log base change of concentration for the 
RHD(885G>T) allele, probe 2. 
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3.3.2 Verification of Results against Blinded Samples 
 
After RHD exon mapping triplexes were deemed specific and sensitive, the 
assays were validated against a panel of 49 unknown samples. Results were 
not concordant with the third party BLOODchip™ data. All controls were 
acceptable, with amplification observed for all exons in the positive control, no 
amplification in the negative or NTC controls and amplification of all internal 
positive controls. However, amplification of exon 2 and exon 9 was not always 
observed in the RHD-CE hybrid alleles. All intact RHD positive alleles were 
detected and all RHD negative alleles did not produce amplification. Table 12 
shows a selection of blinded RHD samples and the relative amplification 
results. Amplification of exon 2 and 9 did not occur for a number of alleles 
where the exons were present, giving false negative results denoted in Table 
12 in red. 
 
 Table 12: Multiplex qPCR amplification results of validation against unknown samples 
   Internal 
Positive 
Control 
Amplification Result 
(Ct) 
  
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 9 Exon 10 Exon CCR5 
Internal 
Negative  
Control 
NTC Negative Negative Negative Negative Negative Negative Negative Negative Negative 
Negative 
Control rr Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.99) 
Negative 
Control 
r’r 
 Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.89) 
Negative 
Control 
r”r 
 Negative Negative Negative Negative Negative Negative Negative Negative 
Positive 
(28.84) 
Positive 
Control R1R2 
Positive 
(27.90) 
Positive 
(26.85) 
Positive 
(29.32) 
Positive 
(26.54) 
Positive 
(28.29) 
Positive 
(28.46) 
Positive 
(31.00) 
Positive 
(27.97) 
Positive 
(29.27) 
Unknown Samples 
Unknown RHD-CE(3-9)-D Negative Negative Negative Negative Negative Negative Negative 
28.37 
Positive 
Positive 
30.56 
Unknown RHD-CE(3-8)-D Negative Negative Negative Negative Negative Negative Negative 
Positive 
29.31 
Positive 
30.33 
Unknown RHD-CE(4-7)-D 
Positive 
27.97 
Positive 
26.94 Negative Negative Negative Negative
Positive 
29.82 
Positive 
28.71 
Positive 
30.06 
Unknown RHD-CE(4-9)-D Negative 
Positive 
29.85 Negative Negative Negative Negative Negative 
Positive 
28.47 
Positive 
31.37 
Unknown RHD-CE(2-7)-D Negative Negative Negative Negative Negative Negative Negative 
Positive 
27.77 
Positive
29.13 
Unknown RHD-CE(3-7)-D Negative Negative Negative Negative Negative Negative Negative 
Positive 
27.23 
Positive 
28.92 
Unknown RHD-CE(2-9)-D Negative Negative Negative Negative Negative Negative Negative 
Positive 
33.22 
Positive 
34.65 
Unknown RHD(9:del/CE) 
Positive 
29.36 
Positive 
30.55 
Positive 
31.37 
Positive 
28.18 
Positive 
36.17 
Positive 
27.77 Negative 
Positive 
28.58 
Positive 
30.05 
Unknown RHD(297del23) 
Positive 
27.46 
Positive 
31.73 
Positive 
30.19 
Positive 
26.83 
Positive 
36.01 
Positive 
26.40 
Positive 
31.01 
Positive 
27.15 
Positive 
28.28 
Unknown RHD(361del11nt) Negative Negative 
Positive 
29.17 
Positive 
26.37 
Positive 
31.58 
Positive 
27.21 Negative 
Positive 
28.55 
Positive 
29.39 
Unknown RHD(K409K) Negative 
Positive 
27.67 
Positive 
28.98 
Positive 
26.51 
Positive 
31.11 
Positive 
25.88 Negative 
Positive 
29.09 
Positive 
30.38 
Unknown R1R2 Positive 28.83 
Positive 
28.91 
Positive 
29.89 
Positive 
25.93 
Positive 
32.11 
Positive 
25.58 
Positive 
32.6 
Positive 
27.00 
Positive 
29.08 
Unknown r”r Negative Negative Negative Negative Negative Negative Negative Negative Positive 27.63 
Unknown r’r Negative Negative Negative Negative Negative Negative Negative Negative Positive 29.20 
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Both the RHD(K409K) and RHD(885G>T) assays were verified against a 
panel of 49 gDNA samples which had been blinded. The RHD(IVS8+1G>A) 
allele was tested against 27 blinded gDNA samples (due to lower prevalence 
of the allele). Results for each allele were 100% concordant with the allelic 
information obtained from the third party CE accredited BLOODchip™ data. 
Validation against blinded samples was not performed for the 
RHD(IVS3+1G>A) and RHD(IVS3+2T>A) or RHD(del343C) alleles as 
specificity for the RHD variants was not achieved.  
3.4 Epitope Mapping 
 
The RhD epitope mapping analysis for uncharacterised RHD alleles revealed 
partial anti-D reactivity patterns for all RHD alleles, with the exception of weak 
D type 10. Table 13 shows the anti-D reactivity patterns of these RHD alleles 
with the D-SCREEN MoAbs. The results suggest that the RHD alleles: 
RHD(94insT), RHD(IVS5-38del4), RHD-CE(9)-D, RHD(IVS1+1G>A), 
RHD(IVS2-2delA), RHD(IVS1+5G>C), RHD(K409K), RHD(IVS8+1G>A) and 
RHD(IVS3+2T>A) express partial RhD epitope mosaics because not all D-
SCREEN MoAbs agglutinated the red cells derived from these RHD alleles 
(Table 13, indicated by -). 
 
Table 13: Extended serological analysis for the DEL phenotype using D-SCREEN 
monoclonal anti-D antibodies 
 
Anti-D MoAb
& 
RhD epitope[120] 
 
P3X249 P3X290 P3X241 P3X35 HM16 P3X61 HM10 P3X21211F1 
P3X212
23B10 
 2.1 3.1 5.4 5.4 6.4 6.4 6.6 8.2 9.1 
RHD allele          
Weak D type 10 
(n=1) 
very 
weak + + + + + + + + 
RHD(94insT) 
(n =4) 
+ + very weak/- + + + - + + 
RHD(IVS1+1G>A) 
(n = 2) 
- - - - - very weak/+ - weak/+ 
very 
weak/+ 
RHD(IVS5-
38del4) (n=1) + + - + + + - + + 
Apparently RHD 
non-neg 
(n=2) 
- - - - - + - + + 
RHD-CE(9)-D 
(n=1) 
weak very weak weak 
very 
weak - - + + + 
RHD(IVS2-2delA) 
(n=1) 
- - - - - + - + + 
RHD(IVS3+2T>A) 
(n=1) - - - - - + - + + 
RHD(K409K) 
(n=1) + weak weak weak weak + - + + 
RHD(IVS1+5G>C) 
(n=1) + + weak + + + - + + 
RHD(IVS8+1G>A) 
(n=1) - - - - - + - + + 
‘weak’ represents a ‘3’ agglutination score. 
‘very weak’ represents a ‘1’ agglutination score. 
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The RHD(94insT) samples showed varying results, with 2 samples giving a 
very weak result for the P3X290 MoAb and 2 samples showing negativity.   
 
Of the two RHD(IVS1+1G>A) samples, one showed clear positivity for 
epitopes 6.4, 8.2 and 9.1, yet the other showed agglutination scores of 1, 3 
and 1 respectively. The RHD(K409K) allele also indicated presence of a 
partial epitope mosaic with positive or weak positive agglutination for all 
MoAbs except HM10. The weak D type 10 was the only allele to show 
reactivity to the full panel of 9 MoAbs.  
 
Included in the epitope mapping were 2 novel alleles, RHD(IVS1+5G>C) and 
RHD(IVS2-2delA), both of which showed partial reactivity. Also tested were 
two donations with seemingly normal RHD profiles, as confirmed by both SNP 
profiling and sequencing. Whilst the genetic composition of these alleles 
remains undefined, the serologic profile indicates a partial epitope mosaic, 
with a positive result for MoAbs P3X61, P3X21211F1 and P3X21223B10 and 
negative results for the remaining MoAbs.  
 
All final wash fractions were free from agglutination, indicating no false 
positives were recorded.  
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There is currently no routine testing for detection of potentially immunogenic 
RhD variants in place at the Blood Service. This project has designed, 
optimised and validated a molecular genotyping method that, if implemented 
in conjunction with current routine serological testing, would greatly improve 
the detection and subsequent removal from the RhD negative donation panel 
of these variants.  A number of these variants have as yet undescribed 
reactivity patterns and hence unknown potential immunogenicity. This project 
has tested the reactivity of these variants against a panel of 9 anti-D 
antibodies, contributing to the current knowledge regarding epitope profiles of 
DEL and RhD variant RBCs. Future research should be focussed on the 
implementation of the assay designed in this project into routine testing at the 
Blood Service and further determination of potential immunogenicity of RhD 
variant RBCs. 
4.1 Extended RHD Exon Mapping 
 
After BLAST alignment of the RHD and RHCE gene, it was evident that it 
would not be possible to design primers and probes around two of the ten 
exons. RHD exon 1 possesses only 1 SNP to RHCE and exon 8 is identical in 
both genes.  
 
It was not always possible to design primers and probes around primarily 
exonic regions. This was due to a number of reasons. In the instance of exon 
2 primers and probe, it was necessary to include a large intronic region in the 
design as 3 of the 4 SNPs between the RHD and RHCE gene as discovered 
by the BLAST alignment are in fact also SNPs between the RHcE and RHCE 
genotypes (RHcE > RHCE:150C>T, 178C>A and 203A>G; RHCE: 307C>T). 
As such the first set of primers and probe were designed around and 
subsequently amplified gDNA extracted from RhD negative, RhC positive 
phenotype (r’r) samples which possesses the RHCe genotype as well as the 
RHD sample. Other causation can be ruled out by the lack of amplification of 
the RHcE samples (r”r phenotype). After redesign of the exon 2 primers and 
probe to anneal to flanking intronic regions,  amplification of the r’r samples 
was eliminated. 
 
Testing of the initial exon 6 primer/probe set continually produced 
amplification in all RHD negative control lanes. The presence of amplification 
in the NTC lane ruled out non-specific binding to the RHCE gene. As such it 
was speculated that amplification was being caused by complementarity 
between the primers and probe, with the predicted interaction shown in Figure 
40. 
forward primer    reverse primer 
 TGGCTGGGCTGATCTCCG             AGAGGTTAGTTGTCTAG 
        TACCGGCAGGTACTTGGCTCC 
            probe 
Figure 39: Speculated interaction of exon 6 primers and probe, causing non-specific 
amplification.  
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A separate assay was completed which tested combinations of forward primer 
and probe; reverse primer and probe; forward primer and reverse primer and 
probe, and dH20 and probe against rr, r’r, r”r, R1R2 and NTC samples. As 
expected, amplification only occurred in the lane containing forward primer, 
reverse primer and probe, supporting the speculated primer dimer formation 
(Figure 40). 
  
Whilst the use of JumpstarTaq eliminated this primer dimer formation, as it 
was important to keep protocols consistent, the primers were redesigned. 
Once redesigned, this primer dimer formation was eliminated and specificity 
for RHD exon 6 was achieved. 
 
Design of exon 9 primers and probe proved considerably difficult to achieve 
specificity to the RHD gene. The original and second set of primers and probe 
did not amplify at 59°C and when tested at a variety of lower temperatures; 
did not show specificity to the RHD gene. The third design of primers involved 
designing 7 different forward primers, a new reverse primer and a new probe. 
Mismatches were introduced in the -1 and -2 positions of the forward primer to 
test for specificity. Primer set 1 and 2, which were the exact match to the RHD 
gene sequence and with a T nucleotide introduced as a mismatch did not 
show specificity, however all other primer sets, which included a C or G 
nucleotide in the -1 position or any nucleotide mismatch in the -2 position, 
showed specificity for the RHD gene. Primer set 1 showed the lowest Ct, 
however was obviously not appropriate for use due to lack of specificity. 
Whilst primer set 5 showed the next lowest Ct value, the amplification curve of 
primer set 7 was more appropriate and as such was chosen for further testing.  
 
During the initial duplex the only combination of primers and probes that 
showed a large difference in amplification was the exon 2 and exon 3 
reaction. Exon 3 was greatly favoured in the reaction and the Ct of exon 2 was 
slightly increased. According to the Applied Biosystems manual for ‘Factors 
Influencing Multiplex Real Time PCR’ when a duplex favours one of the 
primer/probe sets in a reaction, the best course of action is to lower the primer 
concentration of the dominant reaction. This limits the amount of fluorescence 
as the primers are used up, allowing the other primer set to utilise the dNTPs. 
As such, exon 3 primer concentration was decreased to 280nM, 260nM and 
240nM and exon 2 primer concentration was kept at 300nM. Whilst this 
increased the affinity for exon 2, it decreased the integrity of the exon 3 
reaction. It was however, considered sensitive as the correlation coefficient of 
exon 2 was 0.99 and of exon 3 was 0.98. 
 
Following successful duplex, 4plex was trialled to allow for higher throughput. 
However exon 9 and 2, once conjugated with the Cy5 fluorochrome, 
continually did not amplify in the red emission channel. As such, the assay 
was required to be limited to a triplex, rather than the original intended 4plex 
and 5plex to allow for the use of the original VIC and FAM labelled probes. 
This change to research design decreases the amount of concurrent samples 
able to be analysed in a single assay from 15 to 9. Triplex combinations were 
changed to exon 2/7/9; exon 3/4/10 and exon 5/6/CCR5. All triplex sets were 
found to be specific for the RHD gene, however amplification of exon 9 was 
decreased. An increase in both primer and probe was trialled, with a primer 
concentration of 500nM found to be most effective.  
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Overall, the extended RHD exon mapping was successfully specific for the 
RHD gene in a triplex qPCR assay and no primer/probe sets produced non-
specific amplification of the RHCE gene in the optimised assays. 
4.2 SNP Genotyping 
 
As previously mentioned, qPCR assay design for RHD(94insT) DEL detection 
had to be excluded from the study as the T insertion is in a run of 7 Ts, and 
the DNA transcriptase present in the Taq would ‘proof read’ this insertion, 
making it impossible to design primers and probes specific to the DEL allele. 
A possible solution future studies may consider for the detection of the 94insT 
allele would be the design and implementation of a High Resolution Melt 
(HRM) assay that can determine the presence of the extra nucleotide.  
 
The other high frequency DEL alleles and RhD negative associated alleles 
showed varying qPCR amplification results. It was clear that the shorter 
probes were more specific, however designing a probe with a length short 
enough to be specific, yet not lose sensitivity proved difficult. The three most 
common alleles, the RHD(K409K), RHD(885G>T) and RHD(IVS8+1G>A) 
were able to be successfully detected and achieved 100% concordance with 
third party CE accredited BLOODchip data. These assays were specific and 
sensitive across a 4 log base concentration range of 0.01ng to 10ng gDNA 
with acceptable efficiency and reproducibility of results. 
 
The del343C assay was not specific for the RhD negative allele. The probe 
had a Tm of 56.6°C without the inclusion of increased temperature due to the 
MGB modified probe. This was considerable higher than the successful 
probes for the other alleles. There is also a run of 5 C bases at the 5’ end of 
the probe, which may have contributed to the lack of specificity toward the 
del343C allele over the wildtype. Specificity was also not achieved for both the 
RHD(IVS3+2T>A) and RHD(IVS3+1G>A) allele. For reasons currently 
unknown, a distinct lack of amplification occurs during the assay, leading to a 
lack of specificity for the DEL and RhD negative allele.  
 
The LNA probe that was designed and trialled for detection of the 
RHD(K409K) allele did not achieve specificity for the DEL allele across a 
robust temperature range. Specificity was only achieved at an annealing 
temperature of 66°C, and distinction between positive and negative results 
was not clear enough to be considered specific. As such, the MGB probes 
proved to be more appropriate for detection of SNP changes and allelic 
discrimination. 
 
Future research may focus on the redesign of primers and probes for the 
unsuccessful RHD alleles and/or detection via HRM. A shorter probe for the 
RHD(del343C) allele has been designed and ordered, however has not yet 
been validated. Design of primers and probes for the next most common DEL 
and RhD negative alleles in the Australian population may also be considered, 
with cost, efficiency and risk to transfusion recipients taken into consideration. 
 
In conclusion, this project has designed, optimised and validated a quick, 
efficient and specific assay to detect the 2 most common DEL alleles 
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(RHD(K409K) and RHD(885G>T)) and the most common SNP associated 
RhD negative allele (RHD(IVS8+1G>A)) in the Australian population. Red 
cells derived from RHD(K409K) DEL donors have been reported to immunise 
RhD negative transfusion recipients, however current routine serotyping tests 
at the Blood Service do not detect red cells derived from RHD(K409K) donors. 
This qPCR/MGB probe assay is therefore able to conclusively detect and 
correctly classify these DEL alleles. The detection and removal of the alleles 
from the RhD negative donor panel removes the risk of potential immunisation 
of RhD negative patients, contributing to better transfusion protocol and a 
safer RhD negative donor panel.  
4.3 Validation 
 
Whilst RHD exons 3,4,5 and 7 were found to be sensitive across a 6-log base 
sensitivity assay, the remaining sets were not. Whilst this appears to be an 
unsatisfactory result, it can be reasoned that the two outlying concentrations 
(0.001ng and 100ng) can be discounted when considering the unlikeliness of 
either gDNA concentration being extracted from donor whole blood samples 
using the EZ1 system. A minute number of samples exceed 100ng of gDNA 
after extraction from buffy coat and this amount is even lower when extracting 
from whole blood samples. In contrast, the NIPA study; which involves using 
free fetal DNA samples; only measures as low as 0.02ng gDNA. As this study 
includes only whole blood derived gDNA from adult donations, it can safely be 
assumed that no sample with a concentration of less than 0.01ng will ever be 
routinely tested. As such, it was considered acceptable to test robustness of 
the assay across a 4-log base of concentrations, excluding the two extreme 
concentrations.  
 
All RHD exon primer and probe sets were considered robust across this 
range, with a correlation coefficient of 0.99 or greater. No decrease in 
specificity for the RHD gene was observed at the 100ng concentration, 
however a loss in sensitivity was observed at the 0.001ng range, with some 
duplicates not being detected by the Rotor-Gene® at all.   
 
At the duplex level, with the exception of exon 2 and exon 3, all other potential 
exon combinations were found to be sensitive, specific and robust across a 4 
log base concentration sensitivity assay. At the triplex level however, 
limitations were observed, with the Cy5 fluorochrome giving a considerably 
weakened signal than the original FAM and VIC fluorochromes. Different 
concentrations of both primers and probes were trialled, however this did not 
increase fluorescence. After rearrangement of the triplex exon combinations 
to exon 2/7/9; exon 3/4/10 and exon 5/6/CCR5, the assay was found to be 
robust, sensitive and specific across a 4-log base concentration sensitivity 
assay. 
 
Validation against blinded samples yielded unexpected results. All complete 
alleles gave concordant results, with all RHD negative alleles showing no 
amplification and all RHD positive alleles showing amplification of all exons. 
However, in contrast to BLOODchip analysis, a number of RHD-CE hybrid 
alleles showed no amplification of RHD exon 2 and exon 9. All other exons 
showed amplification as expected. This may be due to unreported genetic 
changes in the RHD variants in exon 2 and 9, or it may be due to competition 
of primer/probe sets in the multiplex. The latter seems unlikely however as the 
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R1R2 RHD positive controls showed amplification of all RHD exons and the 
blinded RHD positive alleles with intact exons all gave consistent positive 
amplification of all RHD exons.  
 
Further validation may involve testing of unknown RHD-CE hybrid alleles 
against the singlex exon qPCR assay to determine if amplification occurs 
when the primer/probe sets are not in competition for reagents and gDNA. If 
this also produces a lack of exon 2 and 9 amplification, sequencing of the 
RHD-CE hybrid alleles may be required to determine if the genetic 
composition of these exons is different from an intact RHD positive allele, 
impeding amplification. Further research may involve the implementation of 
different genotyping techniques, such as next generation sequencing or digital 
PCR to detect the presence of the RHD exons.  
 
Of the 6 SNP genotyping assays, those detecting the three most common 
alleles in the Australian population were specific, sensitive and robust across 
a 4-log base concentration sensitivity assay after analysis of the standard 
curve. The shortest probe was found to be the most specific for each allele. 
Whilst the RHD(IVS3+2T>A), RHD(IVS3+1G>A) and RHD(del343C) assays 
were not able to be optimised to be specific for the RHD variant, the three 
most common DEL or RhD negative associated alleles (the RHD(K409K), 
RHD(885G>T) and RHD(IVS8+1G>A) alleles), were able to be detected. 
These assays were also validated against a panel of blinded samples and 
gave 100% concordance with BLOODchip data.   
 
Whilst this project did not conclusively optimise the extended RHD exon 
mapping, it did increase the ability to characterise the exact RHD allele 
present. Exon 3, 4, 5, 6, 7 and 10 of the RHD gene are able to be detected 
across a gDNA range of 0.01ng – 10ng. The two most common DEL 
associated alleles and the most common RhD negative associated allele are 
able to be detected by a specific, sensitive and robust assay that has been 
conclusively validated against a panel of blinded samples.  
4.4 Epitope Mapping 
 
Of the 11 RHD alleles that were selected for extended serological analysis via 
adsorption/elution and IAT, 10 appeared to possess partial epitope mosaics. 
These samples were collected from the r’r/r”r donation panel and are currently 
classified by the Blood Service as RhD negative. The results from this epitope 
mapping indicate that all of the samples show a degree of reactivity with anti-
Ds and as such are potential immunogenic.  
 
Contradictions to current literature include the RHD(IVS8+1G>A), 
RHD(IVS3+2T>A), RHD(K409K) and RHD(IVS5-38del4) alleles. The 
RHD(K409K) allele is considered to possess the full epitope mosaic [24], 
however in this study it was found to be non-reactive with MoAb HM10 and 
only showed weak reactivity with P3X290 P3X241,  P3X35 and HM16. This 
does not necessarily indicate a contradictory result to the current literature, as 
the IAT completed by Körmöczi et al was undertaken via a gel matrix method, 
which may provide greater sensitivity than the in tube IAT method utilised in 
this project [24]. The same may be true of the RHD(IVS5-38del4) allele, as it 
showed no reactivity with the HM10 and P3X241 MoAbs, however Körmöczi 
et al found it to possess a full epitope mosaic.  
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A 2009 paper by Flegel et al concludes that the RHD(IVS3+2T>A) allele is 
non-reactive and as such is determined to be RhD negative [14]. However, the 
results of extended serological screening with a panel of 9 MoAbs found 
reactivity to P3X61, P3X21211F1 and P3X21223B10 antibodies. When this 
allele was initially tested by Dr Scott with the MCAD-6 polyclonal antibody, 3 
of the 4 samples gave a negative result [119]. The Flegel et al study also 
implemented a polyclonal antibody for the IAT, which may indicate that due to 
a change in the epitope profile, the RHD(IVS3+2T>A) allele exhibits a partial 
epitope mosaic and is hence only detectable by certain anti-Ds.  
 
Another contradictory result was obtained for the RHD(IVS8+1G>A) allele. 
RhesusBase lists this allele as having a RhD negative phenotype, with a 2001 
paper by Wagner et al cited [8]. In this paper, the IAT was done using an 
oligoclonal anti-D (Seraclone anti-D blend, clones H4111B7, BS221 and 
BS232; Biotest). Any samples that reacted positive were further tested against 
a similar panel of monoclonal antibodies used in this project, however the 
RHD(IVS8+1G>A) allele did not show agglutination during initial testing and 
was not further investigated. Through further testing against 9 MoAbs, this 
project has shown that the RHD(IVS8+1G>A) allele shows positive reactivity 
with MoAbs P3X61, P3X21211F1 and P3X21223B10.  
 
Red cells from RHD(94insT) donors showed varying results, with 2 samples 
showing weak reactivity of the P3X241 MoAb with epitope 5.4, and 2 samples 
showing no reactivity. This is comparable to results of a similar nature of the 
RHD(885G>T). Samples with the Rhce haplotype exhibit a weak D 
phenotype, whereas samples with the RhCe haplotype show a DEL 
phenotype [90]. Whilst the 4 RHD(94insT) samples tested were of the same 
RhCe phenotype, other unreported SNPs in either the RHD or RHCE gene 
may be affecting RhD antigen expression. 
 
Whilst this has been a limited analysis of the serological profiles of RHD 
alleles, as it utilised only 9 MoAbs, 3 alleles previously considered to be RhD 
negative have been found to exhibit reactivity with anti-Ds. Acquisition of 
samples proved to also be a limitation as donors with previously established 
DEL, RHD-CE hybrids or SNP attributed RhD negativity do not always return.  
 
In conclusion, the reactivity patterns of 11 RHD alleles have been described 
and 10 of these exhibit partial epitope profiles. Two of these donations are 
classified by current literature as RhD negative[8, 119], and all 11 donations are 
all currently classified as RhD negative at the Blood Service. However, these 
results show that these RHD variants all have a degree of reactivity, and 
therefore have the potential for immunogenicity. Future research in this area 
may be focused on confirmation of potential immunogenicity, perhaps via flow 
cytometry and via increased sample numbers.  
  
59 
Chapter 4: Discussion & Conclusion 
4.5 Overall Conclusion 
 
The conclusive agreement of a number of recent blood grouping review 
articles is that molecular genotyping is a vital tool in the management of 
weakly expressed RhD variants[82, 121-124]. Whilst the level of involvement that 
molecular genotyping should have on clinical transfusion management 
remains at odds, a number of European centres have developed some form of 
genotyping strategy for detecting weakly expressed RhD variants[14, 88, 97, 106]. 
There is currently no such strategy in place at the Blood Service in Australia.  
This project has designed, optimised and validated a high throughput, efficient 
and robust assay with the ability to detect the most frequent DEL alleles in the 
Australian population. This includes the RHD(K409K) allele, which has been 
reported to cause both primary and secondary immunisation in a transfusion 
recipient. It has also increased the ability to characterise common RHD-CE 
variants in the donation panel. With further validation, this assay can provide 
supporting genetic information to the current serological testing in place at the 
Blood Service. This will enable the correct classification of RhD positive to 
currently misclassified donations, leading to a decrease of potentially 
immunogenic donations in the RhD negative donation panel and greater 
transfusion safety. Need for outsourcing will be diminished and timeline of 
results will be decreased. 
In addition to this screening assay, this project has determined the reactivity 
patterns of 10 RHD variants with previously undescribed epitope profiles. Of 
these samples, two alleles, the RHD(IVS8+1G>A) and RHD(IVS3+2T>A) 
alleles are described by current literature as RhD negative, however this 
project has determined that they are reactive with anti-D MoAbs and as such 
should be reclassified. Results from two alleles that have been previously 
shown to possess a full epitope profile (the RHD(K409K) and RHD(5-38del4) 
alleles) have indicated the presence of partial reactivity. Two novel alleles, 
RHD(IVS1+5G>C) and RHD(IVS2-2delA), and two apparently RHD positive 
alleles also showed partial reactivity with the panel of MoAbs. All 11 alleles 
that were tested are currently managed as RhD negative donations and may 
be transfused to RhD negative patients. This project has determined that 
these donations all show a level of antigen expression on the RBC surface 
and hence are potentially immunogenic if transfused to an RhD negative 
recipient.  
This project has developed a strategy that, if implemented into routine testing 
of RhD negative, RhC/RhE positive blood donations would place the Blood 
Service at the same level of pretransfusion testing as the leading European 
centres. This strategy of a molecular genotyping assay is supported by 
extended serological analysis of the most common RhD variant phenotypes in 
the Australian population. It allows for the detection and removal of potentially 
immunogenic donations from the RhD negative donation panel. 
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